AU2003218396A1 - Human blood proteins expressed in monocot seeds - Google Patents
Human blood proteins expressed in monocot seeds Download PDFInfo
- Publication number
- AU2003218396A1 AU2003218396A1 AU2003218396A AU2003218396A AU2003218396A1 AU 2003218396 A1 AU2003218396 A1 AU 2003218396A1 AU 2003218396 A AU2003218396 A AU 2003218396A AU 2003218396 A AU2003218396 A AU 2003218396A AU 2003218396 A1 AU2003218396 A1 AU 2003218396A1
- Authority
- AU
- Australia
- Prior art keywords
- protein
- human blood
- plant
- blood protein
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000004506 Blood Proteins Human genes 0.000 title claims description 97
- 108010017384 Blood Proteins Proteins 0.000 title claims description 97
- 241000209510 Liliopsida Species 0.000 title claims description 43
- 108090000623 proteins and genes Proteins 0.000 claims description 140
- 241000196324 Embryophyta Species 0.000 claims description 100
- 102000004169 proteins and genes Human genes 0.000 claims description 94
- 239000000284 extract Substances 0.000 claims description 58
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 claims description 44
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 claims description 44
- 229940024142 alpha 1-antitrypsin Drugs 0.000 claims description 42
- 238000000034 method Methods 0.000 claims description 41
- 239000000203 mixture Substances 0.000 claims description 36
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 33
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 29
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 27
- 229920001184 polypeptide Polymers 0.000 claims description 25
- 150000007523 nucleic acids Chemical group 0.000 claims description 22
- 235000013312 flour Nutrition 0.000 claims description 19
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 17
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 17
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 17
- 150000001413 amino acids Chemical class 0.000 claims description 16
- 108010054147 Hemoglobins Proteins 0.000 claims description 15
- 102000001554 Hemoglobins Human genes 0.000 claims description 15
- 229940106780 human fibrinogen Drugs 0.000 claims description 13
- -1 fibrinogen Proteins 0.000 claims description 12
- 108090000190 Thrombin Proteins 0.000 claims description 11
- 229960004072 thrombin Drugs 0.000 claims description 10
- 230000035800 maturation Effects 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 8
- 125000003147 glycosyl group Chemical group 0.000 claims description 7
- 235000015097 nutrients Nutrition 0.000 claims description 7
- 102000015081 Blood Coagulation Factors Human genes 0.000 claims description 6
- 108010039209 Blood Coagulation Factors Proteins 0.000 claims description 6
- 239000003114 blood coagulation factor Substances 0.000 claims description 6
- 229940019700 blood coagulation factors Drugs 0.000 claims description 6
- 230000031787 nutrient reservoir activity Effects 0.000 claims description 6
- 230000008685 targeting Effects 0.000 claims description 6
- 230000000699 topical effect Effects 0.000 claims description 6
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 claims description 5
- 150000001720 carbohydrates Chemical class 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 239000000356 contaminant Substances 0.000 claims description 4
- 235000016709 nutrition Nutrition 0.000 claims description 4
- 102000037865 fusion proteins Human genes 0.000 claims description 3
- 108020001507 fusion proteins Proteins 0.000 claims description 3
- 230000001131 transforming effect Effects 0.000 claims description 3
- 238000013519 translation Methods 0.000 claims description 3
- 229940088594 vitamin Drugs 0.000 claims description 3
- 239000011782 vitamin Substances 0.000 claims description 3
- 235000013343 vitamin Nutrition 0.000 claims description 3
- 229930003231 vitamin Natural products 0.000 claims description 3
- 238000003306 harvesting Methods 0.000 claims description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 2
- 239000011707 mineral Substances 0.000 claims description 2
- 240000007594 Oryza sativa Species 0.000 description 84
- 235000018102 proteins Nutrition 0.000 description 84
- 235000007164 Oryza sativa Nutrition 0.000 description 82
- 235000009566 rice Nutrition 0.000 description 82
- 210000004027 cell Anatomy 0.000 description 55
- 230000014509 gene expression Effects 0.000 description 50
- 230000009261 transgenic effect Effects 0.000 description 43
- 239000013612 plasmid Substances 0.000 description 23
- 239000013598 vector Substances 0.000 description 23
- 235000013339 cereals Nutrition 0.000 description 20
- 108010049003 Fibrinogen Proteins 0.000 description 19
- 102000008946 Fibrinogen Human genes 0.000 description 19
- 229940012952 fibrinogen Drugs 0.000 description 19
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 17
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 17
- 108020004414 DNA Proteins 0.000 description 17
- 235000001014 amino acid Nutrition 0.000 description 17
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 17
- 239000001099 ammonium carbonate Substances 0.000 description 17
- 238000004519 manufacturing process Methods 0.000 description 17
- 239000000706 filtrate Substances 0.000 description 16
- 241000589158 Agrobacterium Species 0.000 description 14
- 230000009466 transformation Effects 0.000 description 14
- 239000002953 phosphate buffered saline Substances 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 108010068370 Glutens Proteins 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 206010020649 Hyperkeratosis Diseases 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 240000008042 Zea mays Species 0.000 description 10
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 10
- 239000003550 marker Substances 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 108091026890 Coding region Proteins 0.000 description 9
- 239000011536 extraction buffer Substances 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 210000002381 plasma Anatomy 0.000 description 9
- 238000001262 western blot Methods 0.000 description 9
- 102000009123 Fibrin Human genes 0.000 description 8
- 108010073385 Fibrin Proteins 0.000 description 8
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 8
- 244000061176 Nicotiana tabacum Species 0.000 description 8
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 8
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 8
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 229950003499 fibrin Drugs 0.000 description 8
- 108020004707 nucleic acids Proteins 0.000 description 8
- 102000039446 nucleic acids Human genes 0.000 description 8
- 101000823116 Homo sapiens Alpha-1-antitrypsin Proteins 0.000 description 7
- 241000209219 Hordeum Species 0.000 description 7
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 239000000306 component Substances 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 235000009973 maize Nutrition 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 238000006467 substitution reaction Methods 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 235000007340 Hordeum vulgare Nutrition 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 241000209140 Triticum Species 0.000 description 6
- 235000021307 Triticum Nutrition 0.000 description 6
- 230000023555 blood coagulation Effects 0.000 description 6
- 108010031100 chloroplast transit peptides Proteins 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000013604 expression vector Substances 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 238000012545 processing Methods 0.000 description 6
- 230000010076 replication Effects 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 230000035897 transcription Effects 0.000 description 6
- 238000013518 transcription Methods 0.000 description 6
- GUPXYSSGJWIURR-UHFFFAOYSA-N 3-octoxypropane-1,2-diol Chemical compound CCCCCCCCOCC(O)CO GUPXYSSGJWIURR-UHFFFAOYSA-N 0.000 description 5
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 5
- 241000209056 Secale Species 0.000 description 5
- 125000003275 alpha amino acid group Chemical group 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 5
- 235000008504 concentrate Nutrition 0.000 description 5
- 239000012141 concentrate Substances 0.000 description 5
- 239000008367 deionised water Substances 0.000 description 5
- 229910021641 deionized water Inorganic materials 0.000 description 5
- 210000002257 embryonic structure Anatomy 0.000 description 5
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 229920003023 plastic Polymers 0.000 description 5
- 210000002706 plastid Anatomy 0.000 description 5
- 230000008929 regeneration Effects 0.000 description 5
- 238000011069 regeneration method Methods 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- 102000009027 Albumins Human genes 0.000 description 4
- 108010088751 Albumins Proteins 0.000 description 4
- 244000075850 Avena orientalis Species 0.000 description 4
- 102100023804 Coagulation factor VII Human genes 0.000 description 4
- 206010053567 Coagulopathies Diseases 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 4
- 108010014172 Factor V Proteins 0.000 description 4
- 108010023321 Factor VII Proteins 0.000 description 4
- 102000035195 Peptidases Human genes 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- 235000007238 Secale cereale Nutrition 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 239000000443 aerosol Substances 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 210000003763 chloroplast Anatomy 0.000 description 4
- 230000035602 clotting Effects 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 238000011026 diafiltration Methods 0.000 description 4
- 238000009837 dry grinding Methods 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000012882 rooting medium Substances 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 230000005562 seed maturation Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000000108 ultra-filtration Methods 0.000 description 4
- 210000003934 vacuole Anatomy 0.000 description 4
- 238000001238 wet grinding Methods 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 239000005631 2,4-Dichlorophenoxyacetic acid Substances 0.000 description 3
- 241000589155 Agrobacterium tumefaciens Species 0.000 description 3
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 3
- 239000005695 Ammonium acetate Substances 0.000 description 3
- 235000007319 Avena orientalis Nutrition 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 108010071289 Factor XIII Proteins 0.000 description 3
- 102000006395 Globulins Human genes 0.000 description 3
- 108010044091 Globulins Proteins 0.000 description 3
- GRRNUXAQVGOGFE-UHFFFAOYSA-N Hygromycin-B Natural products OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 108010067372 Pancreatic elastase Proteins 0.000 description 3
- 102000016387 Pancreatic elastase Human genes 0.000 description 3
- 108090000113 Plasma Kallikrein Proteins 0.000 description 3
- 239000004695 Polyether sulfone Substances 0.000 description 3
- 108010094028 Prothrombin Proteins 0.000 description 3
- 102100027378 Prothrombin Human genes 0.000 description 3
- 244000062793 Sorghum vulgare Species 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 3
- 229920002494 Zein Polymers 0.000 description 3
- 229940043376 ammonium acetate Drugs 0.000 description 3
- 235000019257 ammonium acetate Nutrition 0.000 description 3
- 229960000723 ampicillin Drugs 0.000 description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 235000005822 corn Nutrition 0.000 description 3
- 229940012413 factor vii Drugs 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- IXORZMNAPKEEDV-OBDJNFEBSA-N gibberellin A3 Chemical compound C([C@@]1(O)C(=C)C[C@@]2(C1)[C@H]1C(O)=O)C[C@H]2[C@]2(C=C[C@@H]3O)[C@H]1[C@]3(C)C(=O)O2 IXORZMNAPKEEDV-OBDJNFEBSA-N 0.000 description 3
- GRRNUXAQVGOGFE-NZSRVPFOSA-N hygromycin B Chemical compound O[C@@H]1[C@@H](NC)C[C@@H](N)[C@H](O)[C@H]1O[C@H]1[C@H]2O[C@@]3([C@@H]([C@@H](O)[C@@H](O)[C@@H](C(N)CO)O3)O)O[C@H]2[C@@H](O)[C@@H](CO)O1 GRRNUXAQVGOGFE-NZSRVPFOSA-N 0.000 description 3
- 229940097277 hygromycin b Drugs 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 235000019713 millet Nutrition 0.000 description 3
- 210000003463 organelle Anatomy 0.000 description 3
- 229920006393 polyether sulfone Polymers 0.000 description 3
- 229940039716 prothrombin Drugs 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000000565 sealant Substances 0.000 description 3
- 229910001220 stainless steel Inorganic materials 0.000 description 3
- 239000010935 stainless steel Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 230000002103 transcriptional effect Effects 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 2
- HZWWPUTXBJEENE-UHFFFAOYSA-N 5-amino-2-[[1-[5-amino-2-[[1-[2-amino-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoic acid Chemical compound C1CCC(C(=O)NC(CCC(N)=O)C(=O)N2C(CCC2)C(=O)NC(CCC(N)=O)C(O)=O)N1C(=O)C(N)CC1=CC=C(O)C=C1 HZWWPUTXBJEENE-UHFFFAOYSA-N 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 235000007558 Avena sp Nutrition 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 102100022641 Coagulation factor IX Human genes 0.000 description 2
- 102100026735 Coagulation factor VIII Human genes 0.000 description 2
- 108010062580 Concanavalin A Proteins 0.000 description 2
- 206010014561 Emphysema Diseases 0.000 description 2
- 108010076282 Factor IX Proteins 0.000 description 2
- 108010080865 Factor XII Proteins 0.000 description 2
- 102000000429 Factor XII Human genes 0.000 description 2
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 2
- 108010061711 Gliadin Proteins 0.000 description 2
- 108010000487 High-Molecular-Weight Kininogen Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 2
- 102100035792 Kininogen-1 Human genes 0.000 description 2
- 102100034869 Plasma kallikrein Human genes 0.000 description 2
- 241000209504 Poaceae Species 0.000 description 2
- 108010083644 Ribonucleases Proteins 0.000 description 2
- 102000006382 Ribonucleases Human genes 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 240000006394 Sorghum bicolor Species 0.000 description 2
- 235000011684 Sorghum saccharatum Nutrition 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 235000019714 Triticale Nutrition 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 108010055615 Zein Proteins 0.000 description 2
- 108010016828 adenylyl sulfate-ammonia adenylyltransferase Proteins 0.000 description 2
- 108010050181 aleurone Proteins 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 239000007844 bleaching agent Substances 0.000 description 2
- 239000010836 blood and blood product Substances 0.000 description 2
- 229960000182 blood factors Drugs 0.000 description 2
- 229940125691 blood product Drugs 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 230000000408 embryogenic effect Effects 0.000 description 2
- 229940012444 factor xiii Drugs 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000003801 milling Methods 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 235000019419 proteases Nutrition 0.000 description 2
- 235000004252 protein component Nutrition 0.000 description 2
- 239000012465 retentate Substances 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000006152 selective media Substances 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000005030 transcription termination Effects 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 108010047303 von Willebrand Factor Proteins 0.000 description 2
- 102100036537 von Willebrand factor Human genes 0.000 description 2
- 229960001134 von willebrand factor Drugs 0.000 description 2
- 241000228158 x Triticosecale Species 0.000 description 2
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
- 108090000344 1,4-alpha-Glucan Branching Enzyme Proteins 0.000 description 1
- 102000003925 1,4-alpha-Glucan Branching Enzyme Human genes 0.000 description 1
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
- INGWEZCOABYORO-UHFFFAOYSA-N 2-(furan-2-yl)-7-methyl-1h-1,8-naphthyridin-4-one Chemical compound N=1C2=NC(C)=CC=C2C(O)=CC=1C1=CC=CO1 INGWEZCOABYORO-UHFFFAOYSA-N 0.000 description 1
- UPMXNNIRAGDFEH-UHFFFAOYSA-N 3,5-dibromo-4-hydroxybenzonitrile Chemical compound OC1=C(Br)C=C(C#N)C=C1Br UPMXNNIRAGDFEH-UHFFFAOYSA-N 0.000 description 1
- CAAMSDWKXXPUJR-UHFFFAOYSA-N 3,5-dihydro-4H-imidazol-4-one Chemical compound O=C1CNC=N1 CAAMSDWKXXPUJR-UHFFFAOYSA-N 0.000 description 1
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
- 108010020183 3-phosphoshikimate 1-carboxyvinyltransferase Proteins 0.000 description 1
- 108010000700 Acetolactate synthase Proteins 0.000 description 1
- 108010013043 Acetylesterase Proteins 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 235000005781 Avena Nutrition 0.000 description 1
- 101710137053 B1-hordein Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 240000002791 Brassica napus Species 0.000 description 1
- 235000011293 Brassica napus Nutrition 0.000 description 1
- 239000005489 Bromoxynil Substances 0.000 description 1
- 101100465058 Caenorhabditis elegans prk-2 gene Proteins 0.000 description 1
- 102000005367 Carboxypeptidases Human genes 0.000 description 1
- 108010006303 Carboxypeptidases Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 241000701489 Cauliflower mosaic virus Species 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 108091033380 Coding strand Proteins 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 206010011686 Cutaneous vasculitis Diseases 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- IMXSCCDUAFEIOE-UHFFFAOYSA-N D-Octopin Natural products OC(=O)C(C)NC(C(O)=O)CCCN=C(N)N IMXSCCDUAFEIOE-UHFFFAOYSA-N 0.000 description 1
- YAHZABJORDUQGO-NQXXGFSBSA-N D-ribulose 1,5-bisphosphate Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)C(=O)COP(O)(O)=O YAHZABJORDUQGO-NQXXGFSBSA-N 0.000 description 1
- 229920002271 DEAE-Sepharose Polymers 0.000 description 1
- 101150074155 DHFR gene Proteins 0.000 description 1
- 101100094857 Danio rerio slc22a6 gene Proteins 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 241001303048 Ditta Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108010001817 Endo-1,4-beta Xylanases Proteins 0.000 description 1
- 108010062466 Enzyme Precursors Proteins 0.000 description 1
- 102000010911 Enzyme Precursors Human genes 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108010014173 Factor X Proteins 0.000 description 1
- 108010074864 Factor XI Proteins 0.000 description 1
- 108010000196 Factor XIIIa Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 239000005562 Glyphosate Substances 0.000 description 1
- 102000007513 Hemoglobin A Human genes 0.000 description 1
- 108010085682 Hemoglobin A Proteins 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 102100031415 Hepatic triacylglycerol lipase Human genes 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000851058 Homo sapiens Neutrophil elastase Proteins 0.000 description 1
- 101000651439 Homo sapiens Prothrombin Proteins 0.000 description 1
- 101000621371 Homo sapiens WD and tetratricopeptide repeats protein 1 Proteins 0.000 description 1
- 101000892274 Human adenovirus C serotype 2 Adenovirus death protein Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 108010077861 Kininogens Proteins 0.000 description 1
- 102000010631 Kininogens Human genes 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 108010028275 Leukocyte Elastase Proteins 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 108020002496 Lysophospholipase Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 240000004658 Medicago sativa Species 0.000 description 1
- 102000036675 Myoglobin Human genes 0.000 description 1
- 108010062374 Myoglobin Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000009869 Neu-Laxova syndrome Diseases 0.000 description 1
- 101100028920 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cfp gene Proteins 0.000 description 1
- 102100033174 Neutrophil elastase Human genes 0.000 description 1
- 108010033272 Nitrilase Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 1
- 101150010952 OAT gene Proteins 0.000 description 1
- 241000209094 Oryza Species 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 240000004713 Pisum sativum Species 0.000 description 1
- 235000010582 Pisum sativum Nutrition 0.000 description 1
- 108700001094 Plant Genes Proteins 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 101710118538 Protease Proteins 0.000 description 1
- 102000002085 Prothrombin/thrombin Human genes 0.000 description 1
- 108050009405 Prothrombin/thrombin Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 101000820656 Rattus norvegicus Seminal vesicle secretory protein 4 Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 102000008847 Serpin Human genes 0.000 description 1
- 108050000761 Serpin Proteins 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108010039811 Starch synthase Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- 208000031737 Tissue Adhesions Diseases 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 241000618809 Vitales Species 0.000 description 1
- 102100023038 WD and tetratricopeptide repeats protein 1 Human genes 0.000 description 1
- 241000209149 Zea Species 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 description 1
- 102000004139 alpha-Amylases Human genes 0.000 description 1
- 108090000637 alpha-Amylases Proteins 0.000 description 1
- 229940024171 alpha-amylase Drugs 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 229940030225 antihemorrhagics Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 101150103518 bar gene Proteins 0.000 description 1
- 238000007630 basic procedure Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 102000006995 beta-Glucosidase Human genes 0.000 description 1
- 108010047754 beta-Glucosidase Proteins 0.000 description 1
- GINJFDRNADDBIN-FXQIFTODSA-N bilanafos Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCP(C)(O)=O GINJFDRNADDBIN-FXQIFTODSA-N 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000004464 cereal grain Substances 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 244000038559 crop plants Species 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000021463 dry cake Nutrition 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 229960004222 factor ix Drugs 0.000 description 1
- 229940012426 factor x Drugs 0.000 description 1
- 238000009313 farming Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000012215 gene cloning Methods 0.000 description 1
- 102000018146 globin Human genes 0.000 description 1
- 108060003196 globin Proteins 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- XDDAORKBJWWYJS-UHFFFAOYSA-N glyphosate Chemical compound OC(=O)CNCP(O)(O)=O XDDAORKBJWWYJS-UHFFFAOYSA-N 0.000 description 1
- 229940097068 glyphosate Drugs 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 150000003278 haem Chemical group 0.000 description 1
- 239000002874 hemostatic agent Substances 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 102000052502 human ELANE Human genes 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 229940039715 human prothrombin Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000006623 intrinsic pathway Effects 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 235000020429 malt syrup Nutrition 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000000442 meristematic effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000006870 ms-medium Substances 0.000 description 1
- AYOOGWWGECJQPI-NSHDSACASA-N n-[(1s)-1-(5-fluoropyrimidin-2-yl)ethyl]-3-(3-propan-2-yloxy-1h-pyrazol-5-yl)imidazo[4,5-b]pyridin-5-amine Chemical compound N1C(OC(C)C)=CC(N2C3=NC(N[C@@H](C)C=4N=CC(F)=CN=4)=CC=C3N=C2)=N1 AYOOGWWGECJQPI-NSHDSACASA-N 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 108010058731 nopaline synthase Proteins 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 150000008278 pentosamines Chemical class 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 238000003976 plant breeding Methods 0.000 description 1
- 239000003375 plant hormone Substances 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 108010067999 preproalbumin Proteins 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000009290 primary effect Effects 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 230000020978 protein processing Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000018883 protein targeting Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 239000004627 regenerated cellulose Substances 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000007226 seed germination Effects 0.000 description 1
- 239000003001 serine protease inhibitor Substances 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical compound OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229960003766 thrombin (human) Drugs 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 229940093612 zein Drugs 0.000 description 1
- 239000005019 zein Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/75—Fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8121—Serpins
- C07K14/8125—Alpha-1-antitrypsin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
- C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
- C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Plant Pathology (AREA)
- Cell Biology (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Description
WO 2004/099405 PCT/US2003/009209 HUMAN BLOOD PROTEINS EXPRESSED IN MONOCOT SEEDS Field of the Inventioni The present invention relates to human blood proteins produced in the seeds of 5 monocot plants for use in making human and animal topical compositions and human therapeutic compositions. Background Of The Invention Many human blood proteins are in short or limited supply due to the larger 10 quantities required of the protein for positive therapeutic effect or possibly also due to the larger demand of these proteins by the world population of patients having the particular condition. It is also advantageous to produce blood proteins, normally extracted from blood products, from an alternative source such as crop plants. Production of blood proteins from plants mitigates contamination of the blood protein 15 fraction with human viruses and other disease causative agents found in human or animal blood product fractions. Blood proteins such as hemoglobin, alpha-1-antitrypsin ("AAT"), fibrinogen, human serum albumin, thrombin, antibodies, blood coagulation factors (e.g. Factors V XIII), and others are known to have therapeutic potential for a number of human 20 conditions. Hemoglobin is the major blood component molecule transporting oxygen to cells. Mammmalian hemoglobins are tetrameric proteins made up of two a-like polypeptide subunits and two non-a (usually P, y, or 6) subunits. These subunits differ in primary amino acid sequence, but have similar secondary and tertiary structures. Each globin 25 subunit has associated with it, by noncovalent interaction, a Fe 2 + -porphyrin complex known as a heme group, to which oxygen binds. The predominant hemoglobin in adult erythrocytes is a2p2, known as hemoglobin A 1 (HbA). Each hemoglobin tetramer has a molecular weight of 64kD and each a-like and p-like chain has a molecular weight of approximately 15.7kD (141 amino acids) and 16.5kD (146 amino acids) respectively. 30 AAT belongs to the class of serpin inhibitors and is one of the major protease inhibitors in human plasma. AAT is a single 394 amino acid polypeptide having an approximate molecular mass of 52kD, and contains about 15% carbohydrate in the native human form of the molecule. Concentrations of AAT in human plasma range from 1000-3000 mg/L and in human milk range from 100 to 400 mg/L. Its primary WO 2004/099405 PCT/US2003/009209 -2 physiological role is the inhibition neutrophil elastase, with an insufficiency leading to the development of pulmonary emphysema. Excess production of elastase activity leads to emphysema, hepatitis and a variety of skin disorders. While the binding affinity of AAT is highest for human neutrophil elastase, it also has affinity for pancreatic proteases 5 such as chymotrypsin and trypsin. The current primary source for the treatment of AAT deficiency is isolating AAT from human blood plasma. Fibrinogen is involved in the blood coagulation cascade and is converted to fibrin by its interaction with the natural clotting agent thrombin. Fibrin is the major component of blood clotting. Mature human fibrinogen consists of two pairs of three independent 10 polypeptide chains (a, P and y) that are linked together by 29 intra- and intermolecular disulfide bonds forming a native protein of 340kD and is present in human plasma at an approximate concentration of 2500 mg/L. Three-dimentional structural analysis of independent fibrinogen domains has provided detailed structural features giving important clues to human fibrinogen's multifunctional role. The fibrinogen polypeptides 15 are approximately 72kD (a), 52kD (P) and 48kD (y) respectively with the P polypeptide chain determining native molecule assembly. The structure of fibrinogen features a number of structural and functional domains containing multiple binding sites that facilitate interactions with itself, other proteins, certain cell types and allow fibrinogen to participate ina number of important physiological processes including blood coagulation, 20 inflammation, angiogenesis, wound closure, artheriogenesis and tumorigenesis. Fibrin formation from a clotting standpoint is mediated by the interaction of native fibrinogen with its natural clotting agents Factor XIII and thrombin in the presence of blood soluble calcium. Albumin is a transport protein molecule that carries out many functions in 25 mammalian serum biology, notably that of a carrier of hormones and other soluble ligands from site to site, and other activities that contribute largely to general mammalian biochemistry. Human serum albumin ("HSA") is also the major protein component of blood being actively present at serum concentrations of approximately 30,000-50,000 mg/L. HSA is a single polypeptide chain of 66.5kD that is initially 30 synthesized as a prepro-albumin molecule in the liver and released from the endoplasmic reticulum after N-terminal and C-terminal Golgi processing. The resultant mature protein is 585 amino acids in length. It has been shown that the natural WO 2004/099405 PCT/US2003/009209 -3 preprosequnce of HSA can function in correct protein targeting/processing across a plant plasma membrane in transgenic tobacco leaves (Sijmons et al, 1990). Prothrombin, a plasma glycoprotein, is the zymogen of the serine protease thrombin that catalyzes the conversion of fibrinogen to fibrin as well as several other 5 reactions that may be important for blood coagulation. Prothrombin is a single polypeptide chain approximately 72,000 molecular weight in size. The complete human thrombin cDNA consists of 622 amino acid residues and includes a leader sequence of 36 amino acid residues. Active thrombin has an apparent molecular weight of 36,000 and is made up of two disulfide-linked polypeptide chains resulting from prothrombin 10 cleavage. The proteolytic events leading to in vitro activation and conversion of human prothrombin to active thrombin have been extremely well characterized. Factors V-XIll are proteins (mostly proteases in their active states) that are involved in the 'intrinsic pathway' of the classical casade mechanism for blood coagulation. The majority of these molecules exist as precursors that are processed in 15 an ordered sequence of transformations from inactive to catalytically active forms. Factor V is proaccelerin (the accelerator globulin) while Factor VI is the activated form of Factor V. Factor VII is proconvertin, the plasma thromboplastin component, while Factors VIII (antihemophilic factor) and IX (Christmas antihemophilic factor) are both associated with the hemophilia disease state. Factors X (Stuart-Power factor), XI 20 (plasma thromboplastin anticedent) and X11 (Hageman factor) are all involved with the maturation/stabilization of thrombin. Factor XIII (fibrin stabilizing factor) is a plasma transglutaminase directly acting on fibrin during the clotting process. All these Factors are present at relatively low in serum plasma (0.001 to 50 mg/L). Other protein factors also involved in the blood coagulation cascade include Fletcher Factor (prekallikrein), 25 Fitzgerald factor (kininogen) and von Willebrand Factor. Immunoglobulins (antibodies) present in humans act to confer resistance to a variety of pathogens to which a patient may have been exposed. Immunoglobulin molecules account for 15-20% of the mass in human serum and consist predominantly of IgG, igM and IgA-type antibodies involved in fighting various infections that invade 30 the blood system and potentially the rest of the body. IgG type antibodies are the most prevelant and exist at a serum concentration of between 6-18 g/L. The blood system also serves as a carrier directing these molecules to specific areas of the body to combat resulting infections and potential oncogenic targets. Mature antibodies consist WO 2004/099405 PCT/US2003/009209 -4 of two polypeptides (light and heavy chains) that must be expressed in eqimolar amounts and come together to form functional entities. The light chain (-25kD) is a protein of -210-240 amino acids in length while the heavy chain (-50kD) is a protein of -450-460 amino acids in length. Both light and heavy chains carry signal peptides for 5 processing and secretion into the blood stream. Expression of monoclonal antibodies in plants is of particular interest, because it requires the expression of two genes, synthesis of two proteins and coerrect assembly of the tetrameric protein to result in a functional antibody. Initial studies of antibodies in plants focused on the IgG antibodiy class (Hiatt et 10 al, 1989; Hiatt and Ma, 1992), but later studies explored the in planta expression of complex antibody molecules such as secretory IgA antibodies (4 genes) and more complex antibody forms (Ma et al, 1995; Vine et al, 2001). U.S. Patent Nos. 6,417,429, 5,959,177, 5,639,947 and 5,202,422, all related patents, disclose the production of antibody molecules in transgenic tobacco plant 15 leaves. U.S. Patent No. 6,303,341 discloses the production of immunoglobulins containing protection proteins in tobacco plant leaves, stems, flowers and roots. Published U.S. Patent Application U.S. 2002/0174453 discloses the production of antibodies in the plastids of tobacco plants. 20 Published U.S. Patent Application U.S. 2002/0046418 discloses a controlled environment agriculture bioreactor for the commercial production of heterologous proteins in transgenic plants. The specification discloses that production of mammalian blood proteins can be achieved. Example 7 discloses the production of human blood factors in the leaves of potato, tobacco and alfalfa plants. 25 U.S. Patent No. 6,344,600 discloses the production of hemoglobin and myoglobin in tobacco plant leaves. Example X discloses the extraction and partial purification of recombinant hemoglobin from tobacco seeds. The expression was obtained by transformation of the coexpression plasmid pBIOC59, which was constructed to allow targeting in the chloroplasts, and contained for this purpose the 30 transit peptide of the precursor of the small subunit of ribulose 1,5-diphosphate carboxylase of Pisum sativum L. Expression in seeds was reported to be at a maximum level of 0.05% recombinant hemoglobin relative to the total soluble proteins extracted.
WO 2004/099405 PCT/US2003/009209 -5 Example XI of the '600 patent discloses the construction of plasmids containing one of the a or P chains of hemoglobin allowing constitutive expression or expression in the albumin in maize seeds. According to this disclosure, the constitutive or albumin specific expression of the hemoglobin chains required the following regulatory 5 sequences: one of three promoters allowing a constitutive expression ((i) the rice actin promoter followed by the rice actin intron, contained in the plasmid pActl-F4; (ii) the 35S double constitutive promoter of cauliflower mosaic virus; or (iii) the promoter of the maize y-zein gene contained in the plasmid py63) and one of two terminators ((i) the 35S polyA terminator; or (ii) the NOS polyA terminator). No experiment or data is 10 provided regarding transformation or expression of these plasmids in maize or maize seeds. U.S. Patent No. 5,767,363 discloses the use of a seed-specific promoter derived from ACP of Brassica napus, to affect and vary the expression of seed oils in rape and tobacco plants. The specification generically discloses that the seed-specific promoter 15 can be used for the expression of pharmaceutical proteins, such as blood factors or human serum albumin, however no experimental data whatsoever is presented in this regard. Daniell et aL (2001) is a review article discussing recent developments in the field of medical molecular farming, including the production of antibodies and proteins in 20 plants. None of these patents or publications discloses the production of human blood proteins in monocot seeds in high yield. It is desirable to provide for the production of human blood proteins in high yield free from contaminating source agents in order to provide the patient population with sufficient supply of these proteins for use in treating 25 humans with conditions treatable by administration of a particular blood protein. Summary Of The Invention In one aspect, the invention includes a method of producing a recombinant human blood protein in monocot plant seeds, comprising the steps of: 30 (a) transforming a monocot plant cell with a chimeric gene comprising (i) a promoter from the gene of a maturation-specific monocot plant storage protein, WO 2004/099405 PCT/US2003/009209 -6 (ii) a first DNA sequence, operably linked to said promoter, encoding a monocot plant seed-specific signal sequence capable of targeting a polypeptide linked thereto to a monocot plant seed endosperm cell, and (iii) a second DNA sequence, linked in translation frame with the first 5 DNA sequence, encoding a human blood protein, wherein the first DNA sequence and the second DNA sequence together encode a fusion protein comprising an N-terminal signal sequence and the human blood protein; (b) growing a monocot plant from the transformed monocot plant cell for a time sufficient to produce seeds containing the human blood protein; and 10 (c) harvesting the seeds from the plant, wherein the human blood protein constitutes at least 3.0% of the total soluble protein in the harvested seeds. The invention also includes a purified human blood protein obtained by the method. Preferably, the human blood protein comprises one or more plant glycosyl 15 groups. The invention also provides a monocot plant seed product, preferably selected from whole seed, flour, extract and malt, prepared from the harvested seeds obtained by the method of the invention. Preferably, the human blood protein constitutes at least 3.0% of the total soluble protein in the seed product. 20 The invention further provides a composition comprising a purified human blood protein, preferably comprising at least one plant glycosyl group, and at least one pharmaceutically acceptable excipient or nutrient, wherein the human blood protein is produced in a monocot plant containing a nucleic acid sequence encoding the human blood protein and is purified from seed harvested from the monocot plant. The nutrient 25 is from a source other than the monocot plant. The formulation can be used for parenteral, enteric, inhalation, intranasal or topical delivery. These and other objects and features of the invention will become more fully apparent when the following detailed description of the invention is read in conjunction with the accompanying drawings and claims. 30 Brief Description of the Figures Figure 1 shows plasmids with constructs containing three codon-optimized genes encoding the fibrinogen polypeptides a (pAPI 398), P (pAPI 417) and y (pAPI 327) (SEQ WO 2004/099405 PCT/US2003/009209 -7 ID NO: 1-3), each under the control of the rice glutelin promoter Gt1. These plasmids, including a plasmid (not shown) containing the hygromycin selectable marker, were bombarded into embryogenic rice callus to create transgenic rice plants expressing these three genes in mature rice seeds. 5 Figure 2 shows a Western blot analysis of transgenic rice lines expressing individual subunits of human fibrinogen. Lane 1, positive control, purified native human fibrinogen (obtained from the Red Cross) showing all three polypeptide chains; Lane 2, extract from Tapei 309, a non transgenic rice variety; Lane 3, molecular weight standard; Lane 4, rice seed extract expressing fibrinogen a chain; Lane 5, rice seed 10 extract expressing fibrinogen P chain; Lane 6, rice seed extract expressing fibrinogen y chain. Total protein extract of rice seeds was performed in 2% SDS, I M urea, 1% pMe and PBS pH 7.4. Fibrinogen polypeptides were detected using antibody recognizing all three chains or individual chains only. Figure 3 shows the simultraneous expression of the three fibrinogen polypeptide 15 chains (a, P and y) in transgenic rice seeds and analyzed via Western blot analysis. Fibrinogen polypeptides and protein aggregates were detected using antibody recognizing all three chains. Figure 3A indicates total protein extracted from rice seeds under non-denaturing conditions (350 mM NaCI, PBS pH 7.4, 0.01 % Tween-20/Trition X-1 00/CHAPS) and run on a non-denaturing 10% acrylamide gel. Lane 1, 1 Ig purified 20 human fibrinogen; Lanes 2 & 3, extracts from Tapei 309, a non-transgenic rice variety; Lane 4, molecular weight markers; Lanes 5 & 7, extracts from two transgenic rice lines where 1.0% pMe was included in the extraction buffer; lanes 6 & 8, extracts from two transgenic rice lines without DMe in the extraction buffer. Lanes 6 & 8 show large protein aggregates that were extracted under non-denaturing conditions from the 25 transgenic lines that run at the approximate position of complexed native human fibrinogen. Figure 3B indicates total protein extracted from rice seeds in 2% SDS, I M urea, 1% pMe and PBS pH 7.4, and run on SDS-PAGE. Lane 1, positive control, native human fibrinogen (obtained from the Red Cross) showing all three polypeptide chains; Lane 2, molecular weight standards; Lanes 3-5, three independent transgenic rice lines 30 expressing all three fibrinigen polypeptides. Figure 4 shows the plasmid pAPI 250 expressing the codon-optimized gene for alpha-1-antitrypsin (AAT) (SEQ ID NO: 5) under the control of the rice glutelin promoter WO 2004/099405 PCT/US2003/009209 -8 Gt1. This plasmid, along with a plasmid (not shown) containing the hygromycin selectable marker gene, was bombarded into embryogenic rice callus to create transgenic rice plants expressing AAT in mature rice seeds. Figure 5 shows Coomassie brilliant blue staining of aqueous phase extraction of 5 transgenic rice grains expressing human recombinant AAT. Both untransformed (rice var. Kitaake) and transgenic rice seeds (-10 pooled R1 seed from five individual transgenic plants) were ground with PBS pH 7.4 buffer. The resulting extract was spun at 14,000 rpm at 4* C for 10 min. Supernatant was collected and -20 pig of this soluble protein extract was resuspended in sample loading buffer, and loaded onto a precast 10 SDS-PAGE gel. Lane 1, molecular weight protein markers; Lane 2, purified non recombinant human AAT; Lane 3, extract from control non-transformed Kitaake variety. Between lanes 2 and 3, the results from the extracts of the five individual transgenic plants are shown. Figure 6 shows Western blot analysis of recombinant human AAT expressed in 15 transgenic rice grains. The R1 pooled seed soluble protein extracts (-10 Ig total protein) from seven independent transgenic rice transformants were prepared as described in Figure 5 above, separated by SDS-PAGE gel and then blotted onto a nitrocellulose filter. The identification of AAT expressed in rice seeds was carried out by Western analysis using anti-AAT antibody. Lane 1, molecular weight protein markers; 20 Lanes 2 & 3, 1 pig and 2 pig, respectively, of purified non-recombinant human AAT; Lanes 4 & 5, control, non-transgenic rice extract (var. Kitaake). The final seven lanes show the results from the extracts of the seven individual transgenic plants. Extracts from two of the seven transgenic lines did not express AAT. The shift in gel mobility between the non-recombinant human and recombinant rice-expressed forms is due to 25 the type and glycosylation differences in the human and recombinant rice-expressed proteins. Figure 7 shows activity of purified recombinant AAT (rAAT) obtained from rice extracts against purified porcine pancreatic elastase (PPE) as determined by Coomassie staining and Western blot analysis. The activity of rAAT is demonstrated by 30 a band shift assay involving the AAT protease substrate, elastase. AAT samples from human and rice ectracts were incubated with equal number of moles of PPE at 37 C for 15 min. Negative control for band shift assay was prepared with the AAT samples WO 2004/099405 PCT/US2003/009209 -9 incubated with equal volume of PPE added. Lane MW refers to molecular weight markers. Figure 7A: Lane 1, purified non-recombinant AAT from human plasma; Lane 2, purified AAT from human plasma + PPE; Lane 3, soluble protein extract containing AAT from transgenic rice seed; Lane 4, protein extract containing AAT from transgenic 5 rice seed + PPE; Lane 5, non-transformed rice seed extract; Lane 6, non-transformed rice seed extract + PPE. Figure 7B shows a shifted band in Lanes 1, 2 and 3. The shifted band, a complex between PPE and an AAT fragment is confirmed to contain AAT by Western blot analysis. The lanes in Figure 7B are analogous to those in Figure 7A. 10 Figure 8 depicts AAT derived from rice cell extracts purified initially through Con A and DEAE Sepharose respectively, then loaded onto an octyl Sepharose column. Octyl Sepharose is the final purification step and separates active AAT from an inactivated form of the protein. Lane 1, molecular weight markers; Lane 2, 2 pig purified non-recombinant human AAT as a standard; Lane 3, pooled eluate from the DEAE 15 Sepharose column. The remaining columns show the flow-through and the eluate from the octyl Sepharose column. Approximately 50 pL from each column fraction was loaded onto an SDS-PAGE gel and the proteins visualized by Coomassie staining. Octyl Sepharose flow-through shows the inactive AAT protein while the eluate resolves active AAT. 20 Figure 9A depicts an AAT association rate constant for activity of purified recombinant AAT against PPE determined (as described by the procedure in Figure 7) using non-recombinant human AAT as a control. Data were generated by Coomassie protein staining and Western blot analysis, as described in Figure 7. Figure 9B depicts the thermostability of plant-derived recombinant AAT versus native human AAT 25 determend by the PPE inhibition assay. Figure 10 shows the plasmid pAPI 9 for expression of codon-optimized human serum albumin (HSA) (SEQ ID NO: 4) under the control of the rice AmylA promoter/signal peptide. This plasmid is useful for the expression of HSA in germinated rice seeds. 30 Figure 11 shows the expression of HSA in transgenic rice seeds. Pooled seed from transgenic rice line 3-11-2 were imbibed in water for 24 hours, then 2 pM gibberelic acid (GA) was added. Seed samples were extracted at 24, 48, 72, and 120 hours post WO 2004/099405 PCT/US2003/009209 -10 GA addition and soluble proteins were extracted and prepared for Western analysis. 15 gg of soluble protein were loaded onto each lane along with protein isolated from the non-transfromed negative control line TP309. The blot was probed with monoclonal antibody prepared against HSA. 5 Detailed Description of the Invention Unless otherwise indicated, all terms used herein have the meanings given below or are generally consistent with same meaning that the terms have to those skilled in the art of the present invention. Practitioners are particularly directed to 10 Sambrook et aL (1989) Molecular Cloning: A Laboratory Manual (Second Edition), Cold Spring Harbor Press, Plainview, N.Y., Ausubel FM et al. (1993) Current Protocols in Molecular Biology, John Wiley & Sons, New York, N.Y., and Gelvin and Schilperoot, eds. (1997) Plant Molecular Biology Manual, Kluwer Academic Publishers, The Netherlands for definitions and terms of the art. 15 The polynucleotides of the invention may be in the form of RNA or in the form of DNA, and include messenger RNA, synthetic RNA and DNA, cDNA, and genomic DNA. The DNA may be double-stranded or single-stranded, and if single-stranded may be the coding strand or the non-coding (anti-sense, complementary) strand. The term "stably transformed" with reference to a plant cell means the plant cell 20 has a non-native (heterologous) nucleic acid sequence integrated into its genome which is maintained through two or more generations. By "host cell" is meant a cell containing a vector and supporting the replication and/or transcription and/or expression of the heterologous nucleic acid sequence. Preferably, according to the invention, the host cell is a monocot plant cell. Other host 25 cells may be used as secondary hosts, including bacterial, yeast, insect, amphibian or mammalian cells, to move DNA to a desired plant host cell. A "plant cell" refers to any cell derived from a plant, including undifferentiated tissue (e.g., callus) as well as plant seeds, pollen, propagules, embryos, suspension cultures, meristematic regions, leaves, roots, shoots, gametophytes, sporophytes and 30 microspores. The term "mature plant" refers to a fully differentiated plant.
WO 2004/099405 PCT/US2003/009209 -11 The term "seed product" includes, but is not limited to, seed fractions such as de hulled whole seed, flour (seed that has been de-hulled by milling and ground into a powder) a seed extract, preferably a protein extract (where the protein fraction of the flour has been separated from the carbohydrate fraction), malt (including malt extract or 5 malt syrup) and/or a purified protein fraction derived from the transgenic grain. The term "biological activity" refers to any biological activity typically attributed to that protein by those of skill in the art. The term "blood protein" refers to one or more proteins, or biologically active fragments thereof, found in normal human blood, including, without limitation, 10 hemoglobin, alpha-1-antitrypsin, fibrinogen, human serum albumin, prothrombin/thrombin, antibodies, blood coagulation factors (Factor V, Factor VI, Factor VII, Factor VII, Factor IX, Factor X, Factor XI, Factor XII, Factor XIIl, Fletcher Factor, Fitzgerald Factor and von Willebrand Factor), and biologically active fragments thereof. The term "non-nutritional" refers to a pharmaceutically acceptable excipient 15 which does not as its primary effect provide nutrition to the recipient. Preferably, it may provide one of the following services to an enterically delivered formulation, including acting as a carrier for a therapeutic protein, protecting the protein from acids in the digestive tract, providing a time-release of the active ingredients being delivered, or otherwise providing a useful quality to the formulation in order to administer to the patient 20 the blood proteins. "Monocot seed components" refers to carbohydrate, protein, and lipid components extractable from monocot seeds, typically mature monocot seeds. "Seed maturation" refers to the period starting with fertilization in which metabolizable reserves, e.g., sugars, oligosaccharides, starch, phenolics, amino acids, 25 and proteins, are deposited, with and without vacuole targeting, to various tissues in the seed (grain), e.g., endosperm, testa, aleurone layer, and scutellar epithelium, leading to grain enlargement, grain filling, and ending with grain desiccation. "Maturation-specific protein promoter" refers to a promoter exhibiting substantially upregulated activity (greater than 25%) during seed maturation. 30 "Heterologous DNA" refers to DNA which has been introduced into plant cells from another source, or which is from a plant source, including the same plant source, but which is under the control of a promoter that does not normally regulate expression of the heterologous DNA.
WO 2004/099405 PCT/US2003/009209 -12 "Heterologous protein" is a protein encoded by a heterologous DNA. A "signal sequence" is an N- or C-terminal polypeptide sequence which is effective to localize the peptide or protein to which it is attached to a selected intracellular or extracellular region. Preferably, according to the invention, the signal 5 sequence targets the attached peptide or protein to a location such as an endosperm cell, more preferably an endosperm-cell organelle, such as an intracellular vacuole or other protein storage body, chloroplast, mitochondria, or endoplasmic reticulum, or extracellular space, following secretion from the host cell. Expression vectors for use in the present invention are chimeric nucleic acid 10 constructs (or expression vectors or cassettes), designed for operation in plants, with associated upstream and downstream sequences. In general, expression vectors for use in practicing the invention include the following operably linked components that constitute a chimeric gene: a promoter from the gene of a maturation-specific monocot plant storage protein, a first DNA sequence, 15 operably linked to the promoter, encoding a monocot plant seed-specific signal sequence (such as an N-terminal leader sequence or a C-terminal trailer sequence) capable of targeting a polypeptide linked thereto to an endosperm cell, preferably an endosperm-cell organelle, such as a protein storage body, and a second DNA sequence, linked in translation frame with the first DNA sequence, encoding a human 20 blood protein. The signal sequence is preferably cleaved from the human blood protein in the plant cell. The chimeric gene, in turn, is typically placed in a suitable plant-transformation vector having (i) companion sequences upstream and/or downstream of the chimeric gene which are of plasmid or viral origin and provide necessary characteristics to the 25 vector to permit the vector to move DNA from bacteria to the desired plant host; (ii) a selectable marker sequence; and (iii) a transcriptional termination region generally at the opposite end of the vector from the transcription initiation regulatory region. Numerous types of appropriate expression vectors, and suitable regulatory sequences are known in the art for a variety of plant host cells. The promoter region is 30 chosen to be regulated in a manner allowing for induction under seed-maturation conditions. In one aspect of this embodiment of the invention, the expression construct includes a promoter which exhibits specifically upregulated activity during seed maturation. Promoters for use in the invention are typically derived from cereals such WO 2004/099405 PCT/US2003/009209 -13 as rice, barley, wheat, oat, rye, corn, millet, triticale or sorghum. Examples of such promoters include the maturation-specific promoter region associated with one of the following maturation-specific monocot plant storage proteins: rice glutelins, oryzins, and prolamines, barley hordeins, wheat gliadins and glutelins, maize zeins and glutelins, oat 5 glutelins, and sorghum kafirins, millet pennisetins, and rye secalins. Exemplary regulatory regions from these genes are exemplified by SEQ ID NOS: 6-14. Other promoters suitable for expression in maturing seeds include the barley endosperm specific B1-hordein promoter, GluB-2 promoter, Bx7 promoter, Gt3 promoter, GluB-1 promoter and Rp-6 promoter, particularly if these promoters are used in conjunction with 10 transcription factors. Of particular interest is the expression of the nucleic acid encoding a human blood protein from a promoter that is preferentially expressed in plant seed tissue. Examples of such promoter sequences include those sequences derived from sequences encoding plant storage protein genes or from genes involved in fatty acid 15 biosynthesis in oilseeds. Exemplary preferred promoters include a glutelin (Gtl) promoter, as exemplified by SEQ ID NO: 6, which effects gene expression in the outer layer of the endosperm, and a globulin (Glb) promoter, as exemplfieid by SEQ ID NO: 7, which effects gene expression in the center of the endosperm. Promoter sequences for regulating transcription of gene coding sequences operably linked thereto include 20 naturally-occurring promoters, or regions thereof capable of directing seed-specific transcription, and hybrid promoters, which combine elements of more than one promoter. Methods for construction such hybrid promoters are well known in the art. In some cases, the promoter is native to the same plant species as the plant cells into which the chimeric nucleic acid construct is to be introduced. In other 25 embodiments, the promoter is heterologous to the plant host cell. Alternatively, a seed-specific promoter from one type of monocot may be used regulate transcription of a nucleic acid coding sequence from a different monocot or a non-cereal monocot. In addition to encoding the protein of interest, the expression cassette or 30 heterologous nucleic acid construct includes DNA encoding a signal peptide that allows processing and translocation of the protein, as appropriate. Exemplary signal sequences are those sequences associated with the monocot maturation-specific genes: glutelins, prolamines, hordeins, gliadins, glutenins, zeins, albumin, globulin, ADP WO 2004/099405 PCT/US2003/009209 -14 glucose pyrophosphorylase, starch synthase, branching enzyme, Em, and lea. Exemplary sequences encoding a signal peptide for a protein storage body are identified herein as SEQ ID NOS: 15-21. In one preferred embodiment, the method is directed toward the localization of 5 proteins in an endosperm cell, preferably an endosperm-cell organelle, such as a protein storage body, mitochondrion, endoplasmic reticulum, vacuole, chloroplast or other plastidic compartment. For example, when proteins are targeted to plastids, such as chloroplasts, in order for expression to take place the construct also employs the use of sequences to direct the gene product to the plastid. Such sequences are referred to 10 herein as chloroplast transit peptides (CTP) or plastid transit peptides (PTP). In this manner, when the gene of interest is not directly inserted into the plastid, the expression construct additionally contains a gene encoding a transit peptide to direct the gene of interest to the plastid. The chloroplast transit peptides may be derived from the gene of interest, or may be derived from a heterologous sequence having a CTP. Such transit 15 peptides are known in the art. See, for example, (Smeekens et al., 1986; Wasmann et aL., 1986; Von Heijne et aL, 1991, U.S. patents 4,940,835 and 5,728,925; . Additional transit peptides for the translocation of the protein to the endoplasmic reticulum (ER) (Chrispeels, 1991; Vitale and Chrispeels, 1992), nuclear localization signals (Shieh et aL, 1993; Varagona et al., 1992)or vacuole (Raikhel and Chrispeels 1992; Bednarek 20 and Raikel, 1992; also see U.S. Patent No 5,360,726) may also find use in the constructs of the present invention. Another exemplary class of signal sequences are sequences effective to promote secretion of heterologous protein from aleurone cells during seed germination, including the signal sequences associated with alpha-amylase, protease, carboxypeptidase, 25 endoprotease, ribonuclease, DNase/RNase, (1-3)-beta-glucanase, (1-3)(1-4)-beta glucanase, esterase, acid phosphatase, pentosamine, endoxylanase, p xylopyranosidase, arabinofuranosidase, beta-glucosidase, (1-6)-beta-glucanase, perioxidase, and lysophospholipase. Since many protein storage proteins are under the control of a maturation 30 specific promoter, and this promoter is operably linked to a signal sequence for targeting to a protein body, the promoter and signal sequence can be isolated from a single protein-storage gene, then operably linked to a blood protein in the chimeric gene construction. One preferred and exemplary promoter-signal sequence is from the rice WO 2004/099405 PCT/US2003/009209 -15 Gt1 gene, having an exemplary sequence identified by SEQ ID NO: 6. Alternatively, the promoter and leader sequence may be derived from different genes. One preferred and exemplary promoter-signal sequence combination is the rice Gib promoter linked to the rice Gtl leader sequence, as exemplified by SEQ ID NO: 7. 5 Preferably, expression vectors or heterologous nucleic acid constructs designed for operation in plants comprise companion sequences upstream and downstream to the expression cassette. The companion sequences are of plasmid or viral origin and provide necessary characteristics to the vector to permit the vector to move DNA from a secondary host to the plant host, such as, sequences containing an origin of replication 10 and a selectable marker. Typical secondary hosts include bacteria and yeast. In one embodiment, the secondary host is E. coi, the origin of replication is a CoIE1 -type, and the selectable marker is a gene encoding ampicillin resistance. Such sequences are well known in the art and are commercially available as well (e.g., Clontech, Palo Alto, Calif.; Stratagene, La Jolla, CA). 15 The transcription termination region may be taken from a gene where it is normally associated with the transcriptional initiation region or may be taken from a different gene. Exemplary transcriptional termination regions include the NOS terminator from Agrobacterium Ti plasmid and the rice c-amylase terminator. Polyadenylation tails may also be added to the expression cassette to optimize 20 high levels of transcription and proper transcription termination, respectively. Polyadenylation sequences include, but are not limited to, the Agrobacterium octopine synthetase signal, or the nopaline synthase of the same species. Suitable selectable markers for selection in plant cells include, but are not limited to, antibiotic resistance genes, such as, kanamycin (nptll), G418, bleomycin, 25 hygromycin, chloramphenicol, ampicillin, tetracycline, and the like. Additional selectable markers include a bar gene which codes for bialaphos resistance; a mutant EPSP synthase gene which encodes glyphosate resistance; a nitrilase gene which, confers resistance to bromoxynil; a mutant acetolactate synthase gene (ALS) which confers imidazolinone or sulphonylurea resistance; and a methotrexate resistant DHFR gene. 30 The particular marker gene employed is one which allows for selection of transformed cells as compared to cells lacking the DNA which has been introduced. Preferably, the selectable marker gene is one which facilitates selection at the tissue culture stage, e.g., a kanamyacin, hygromycin or ampicillin resistance gene.
WO 2004/099405 PCT/US2003/009209 -16 The vectors of the present invention may also be modified to include intermediate plant transformation plasmids that contain a region of homology to an Agrobacterium tumefaciens vector, a T-DNA border region from Agrobacterium tumefaciens, and chimeric genes or expression cassettes (described above). Further, the vectors of the 5 invention may comprise a disarmed plant tumor inducing plasmid of Agrobacterium tumefaciens. In general, a selected nucleic acid sequence is inserted into an appropriate restriction endonuclease site or sites in the vector. Standard methods for cutting, ligating and transformation into a secondary host cell, known to those of skill in the art, 10 are used in constructing vectors for use in the present invention. (See generally, Maniatis et aL, Ausubel et aL, and Gelvin et aL., supra.) Plant cells or tissues are transformed with expression constructs (heterologous nucleic acid constructs, e.g., plasmid DNA into which the gene of interest has been inserted) using a variety of standard techniques. Effective introduction of vectors in 15 order to facilitate enhanced plant gene expression is an important aspect of the invention. It is preferred that the vector sequences be stably transformed, preferably integrated into the host genome. The method used for transformation of host plant cells is not critical to the present invention. The skilled artisan will recognize that a wide variety of transformation 20 techniques exist in the art, and new techniques are continually becoming available. Any technique that is suitable for the target host plant may be employed within the scope of the present invention. For example, the constructs can be introduced in a variety of forms including, but not limited to, as a strand of DNA, ina plasmid, or in an artificial chromosome. The introduction of the constructs into the target plant cells can be 25 accomplished by a variety of techniques, including, but not limited to calcium phosphate-DNA co-precipitation, electroporation, microinjection, Agrobacterium mediated transformation, liposome-mediated transformation, protoplast fusion or microprojectile bombardment (Christou, 1992; Sanford et aL., 1993). The skilled artisan can refer to the literature for details and select suitable techniques for use in the 30 methods of the present invention. When Agrobacterium is used for plant cell transformation, a vector is introduced into the Agrobacterium host for homologous recombination with T-DNA or the Ti- or Ri plasmid present in the Agrobacterium host. The Ti- or Ri-plasmid containing the T-DNA WO 2004/099405 PCT/US2003/009209 -17 for recombination may be armed (capable of causing gall formation) or disarmed (incapable of causing gall formation), the latter being permissible, so long as the vir genes are present in the transformed Agrobacterium host. The armed plasmid can give a mixture of normal plant cells and gall. 5 In some instances where Agrobacterium is used as the vehicle for transforming host plant cells, the expression or transcription construct bordered by the T-DNA border region(s) is inserted into a broad host range vector capable of replication in E. coil and Agrobacterium, examples of which are described in the literature, for example pRK2 or derivatives thereof. See, for example, Ditta et aL, 1980 and EPA 0 120 515. 10 Alternatively, one may insert the sequences to be expressed in plant cells into a vector containing separate replication sequences, one of which stabilizes the vector in E. coli, and the other in Agrobacterium. See, for example, McBride and Summerfelt 1990, wherein the pRiHRI (Jouanin, et aL., 1985), origin of replication is utilized and provides for added stability of the plant expression vectors in host Agrobacterium cells. 15 Included with the expression construct and the T-DNA is one or more selectable marker coding sequences which allow for selection of transformed Agrobacterium and transformed plant cells. A number of antibiotic resistance markers have been developed for use with plant cells, these include genes inactivating antibiotics such as kanamycin, the aminoglycoside G418, hygromycin, or the like. The particular marker 20 employed is not essential to this invention, with a particular marker preferred depending on the particular host and the manner of construction. For Agrobacterium-mediated transformation of plant cells, explants are incubated with Agrobacterium for a time sufficient to result in infection, the bacteria killed, and the plant cells cultured in an appropriate selection medium. Once callus forms, shoot 25 formation can be encouraged by employing the appropriate plant hormones in accordance with known methods and the shoots transferred to rooting medium for regeneration of plants. The plants may then be grown to seed and the seed used to establish repetitive generations and for isolation of the recombinant protein produced by the plants. 30 There are a number of possible ways to obtain plant cells containing more than one expression construct. In one approach, plant cells are co-transformed with a first and second construct by inclusion of both expression constructs in a single transformation vector or by using separate vectors, one of which expresses desired WO 2004/099405 PCT/US2003/009209 -18 genes. The second construct can be introduced into a plant that has already been transformed with the first expression construct, or alternatively, transformed plants, one having the first construct and one having the second construct, can be crossed to bring the constructs together in the same plant. 5 In a preferred embodiment, the plants used in the methods of the present invention are derived from members of the taxonomic family known as the Gramineae. This includes all members of the grass family of which the edible varieties are known as cereals. The cereals include a wide variety of species such as wheat (Triticum sps.), rice (Oryza sps.) barley (Hordeum sps.) oats, (Avena sps.) rye (Secale sps.), corn 10 (maize) (Zea sps.) and millet (Pennisettum sps.). In practicing the present invention, preferred grains are rice, wheat, maize, barley, rye and triticale, and most preferred is rice. In order to produce transgenic plants that express human blood protein in seeds, monocot plant cells or tissues derived from them are transformed with an expression 15 vector comprising the coding sequence for a human blood protein. The transgenic plant cells are cultured in medium containing the appropriate selection agent to identify and select for plant cells which express the heterologous nucleic acid sequence. After plant cells that express the heterologous nucleic acid sequence are selected, whole plants are regenerated from the selected transgenic plant cells. Techniques for regenerating 20 whole plants from transformed plant cells are generally known in the art. Transgenic plant lines, e.g., rice, wheat, corn or barely, can be developed and genetic crosses carried out using conventional plant breeding techniques. Transformed plant cells are screened for the ability to be cultured in selective media having a threshold concentration of a selective agent. Plant cells that grow on or 25 in the selective media are typically transferred to a fresh supply of the same media and cultured again. The explants are then cultured under regeneration conditions to produce regenerated plant shoots. After shoots form, the shoots are transferred to a selective rooting medium to provide a complete plantlet. The plantlet may then be grown to provide seed, cuttings, or the like for propagating the transformed plants. The 30 method provides for efficient transformation of plant cells and regeneration of transgenic plants, which can produce a recombinant human blood protein. The expression of the recombinant human blood protein may be confirmed using standard analytical techniques such as Western blot, ELISA, PCR, HPLC, NMR, or WO 2004/099405 PCT/US2003/009209 -19 mass spectroscopy, together with assays for a biological activity specific to the particular protein being expressed. A purified blood protein recombinantly produced in a plant cell, preferably substantially free of contaminants of the host plant cell, and preferably comprising at 5 least one plant glycosyl group is also provided by the invention. The plant glycosyl groups, while identifying that the blood protein was produced in a plant, does not significantly impair the biological activity of the blood protein in any of the applied therapeutic contexts (preferably less than 25% loss of activity, more preferably less than 10% loss of activity, as compared to a corresponding non-recombinant human blood 10 protein). Typically, in accordance with some embodiments of the invention, the human blood protein constitutes at least about 0.5%, at least about 1.0% or at least about 2.0% of the total soluble protein in the seeds harvested from the transgenic plant. In a preferred embodiment, however, protein expression is much higher than previously reported, i.e., at least about 3.0%, which makes commercial production quite feasible. 1,5 Advantageously, protein expression is at least about 5.0%, at least about 10%, at least about 15%, at least about 20%, at least about 30%, or even at least about 40% of total soluble protein. The invention includes plant seed product prepared from the harvested seeds. Preferably, the human blood protein constitutes at least about 3.0% of the total soluble 20 protein in the seed product, more preferably at least about 5.0%, and most preferably at least about 10.0%. As shown in the figures, the expression of human blood proteins in rice grains, represented by AAT, the three fibrinogen polypeptides and HSA represent at least about 10% of total soluble protein. The present invention also provides compositions comprising human blood 25 proteins produced recombinantly in the seeds of monocot plants, and methods of making such compositions. In practicing the invention, a human blood protein is produced in the seeds or grain of transgenic plants that express the nucleic acid coding sequence for the human blood protein. After expression, the blood protein may be provided to a patient in substantially unpurified form (i.e., at least 20% of the 30 composition comprises plant material), or the blood protein may be isolated or purified from a product of the mature seed (e.g., flour, extract, malt or whole seed, etc.) and formulated for delivery to a patient.
WO 2004/099405 PCT/US2003/009209 -20 Such compositions can comprise a formulation for the type of delivery intended. Delivery types can include, e.g. parenteral, enteric, inhalation, intranasal or topical delivery. Parenteral delivery can include, e.g. intravenous, intramuscular, or suppository. Enteric delivery can include, e.g. oral administration of a pill, capsule, or 5 other formulation made with a non-nutritional pharmaceutically-acceptable excipient, or a composition with a nutrient from the transgenic plant, for example, in the grain extract in which the protein is made, or from a source other than the transgenic plant. Such nutrients include, for example, salts, saccharides, vitamins, minerals, amino acids, peptides, and proteins other than the human blood protein. Intranasal and inhalant 10 delivery systems can include spray or aerosol in the nostrils or mouth. Topical delivery can include, e.g. creams, topical sprays, or salves. Preferably, the composition is substantially free of contaminants of the transgenic plant, preferably containing less than 20% plant material, more preferably less than 10%, and most preferably, less than 5%. The preferable route of administration is enteric, and preferably the composition is 15 non-nutrititional. The blood protein can be purified from the seed product by a mode including grinding, filtration, heat, pressure, salt extraction, evaporation, or chromatography. The human blood proteins produced in accordance with the invention also include all variants thereof, whether allelic variants or synthetic variants. A "variant" 20 human blood protein-encoding nucleic acid sequence may encode a variant human blood protein amino acid sequence that is altered by one or more amino acids from the native blood protein sequence, preferably at least one amino acid substitution, deletion or insertion. The nucleic acid substitution, insertion or deletion leading to the variant may occur at any residue within the sequence, as long as the encoded amino acid 25 sequence maintains substantially the same biological activity of the native human blood protein. In another embodiment, the variant human blood protein nucleic acid sequence may encode the same polypeptide as the native sequence but, due to the degeneracy of the genetic code, the variant has a nucleic acid sequence altered by one or more bases from the native polynucleotide sequence. 30 The variant nucleic acid sequence may encode a variant amino acid sequence that contains a "conservative" substitution, wherein the substituted amino acid has structural or chemical properties similar to the amino acid which it replaces and physicochemical amino acid side chain properties and high substitution frequencies in WO 2004/099405 PCT/US2003/009209 -21 homologous proteins found in nature (as determined, e.g., by a standard Dayhoff frequency exchange matrix or BLOSUM matrix). In addition, or alternatively, the variant nucleic acid sequence may encode a variant amino acid sequence containing a "non conservative" substitution, wherein the substituted amino acid has dissimilar structural 5 or chemical properties to the amino acid it replaces. Standard substitution classes include six classes of amino acids based on common side chain properties and highest frequency of substitution in homologous proteins in nature, as is generally known to those of skill in the art and may be employed to develop variant human blood protein encoding nucleic acid sequences. 10 As will be understood by those of skill in the art, in some cases it may be advantageous to use a human blood protein-encoding nucleotide sequences possessing non-naturally occurring codons. Codons preferred by a particular eukaryotic host can be selected, for example, to increase the rate of human blood protein expression or to produce recombinant RNA transcripts having desirable properties, 15 such as a longer half-life, than transcripts produced from naturally occurring sequence. As an example, it has been shown that codons for genes expressed in rice are rich in guanine (G) or cytosine (C) in the third codon position (Huang et al., 1990). Changing low G + C content to a high G + C content has been found to increase the expression levels of foreign protein genes in barley grains (Horvath et aL., 2000). The blood protein 20 encoding genes employed in the present invention were synthesized by Operon Technologies (Alameda, CA) based on the rice gene codon bias (Huang et al., 1990) along with the appropriate restriction sites for gene cloning. These 'codon-optimized' genes were linked to regulatory/secretion sequences for seed-directed monocot expression and these chimeric genes then inserted into the appropriate plant 25 transformation vectors. A human blood protein-encoding nucleotide sequence may be engineered in order to alter the human blood protein coding sequence for a variety of reasons, including but not limited to, alterations which modify the cloning, processing and/or expression of the human blood protein by a cell. 30 Heterologous nucleic acid constructs may include the coding sequence for a given human blood protein (i) in isolation; (ii) in combination with additional coding sequences; such as fusion protein or signal peptide, in which the human blood protein coding sequence is the dominant coding sequence; (iii) in combination with non-coding WO 2004/099405 PCT/US2003/009209 -22 sequences, such as introns and control elements, such as promoter and terminator elements or 5' and/or 3' untranslated regions, effective for expression of the coding sequence in a suitable host; and/or (iv) in a vector or host environment in which the human blood protein coding sequence is a heterologous gene. 5 Depending upon the intended use, an expression construct may contain the nucleic acid sequence encoding the entire human blood protein, or a portion thereof. For example, where human blood protein sequences are used in constructs for use as a probe, it may be advantageous to prepare constructs containing only a particular portion of the human blood protein encoding sequence, for example a sequence which is 10 discovered to encode a highly conserved human blood protein region. The invention provides, in one embodiment, a seed composition containing a flour, extract, or malt obtained from mature monocot seeds and one or more seed produced human blood proteins in unpurified form. Isolating the blood proteins from the flour can entail forming an extract composition by milling seeds to form a flour, 15 extracting the flour with an aqueous buffered solution, and optionally, further treating the extract to partially concentrate the extract and/or remove unwanted components. In a preferred method, mature monocot seeds, such as rice seeds, are milled to a flour, and the flour then suspended in saline or in a buffer, such as Phosphate Buffered Saline ("PBS"), ammonium bicarbonate buffer, ammonium acetate buffer or Tris buffer. A 20 volatile buffer or salt, such as ammonium bicarbonate or ammonium acetate may obviate the need for a salt-removing step, and thus simplify the extract processing method. The flour suspension is incubated with shaking for a period typically between 30 minutes and 4 hours, at a temperature between 20-55"C. The resulting homogenate is 25 clarified either by filtration or centrifugation. The clarified filtrate or supernatant may be further processed, for example by ultrafiltration or dialysis or both to remove contaminants such as lipids, sugars and salt. Finally, the material maybe dried, e.g., by lyophilization, to form a dry cake or powder. The extract combines advantages of high blood-protein yields, essentially limiting losses associated with protein purification. 30 In general, the protein once produced in a product of a mature seed can be further purified by standard methods known in the art, such as by filtration, affinity column, gel electrophoresis, and other such standard procedures. The purified protein can then be formulated as desired for delivery to a human patient. More than one WO 2004/099405 PCT/US2003/009209 -23 protein can be combined for the therapeutic formulation. The protein may be purified and used in biomedical applications requiring a non-food administration of the protein. The following examples illustrate but are not intended in any way to limit the invention. 5 EXAMPLE 1 Production of transgenic rice encoding AAT and fibrinogen polypeptides The basic procedures of particle bombardment-mediated rice transformation and plant regeneration were carried out as described by Huang et al., 2001. Rice variety 10 TP309 seeds were dehusked, sterilized in 50% (v/v) commercial bleach for 25 min and washed with sterile water. The sterilized seeds were placed on rice callus induction medium .(RCI) plates containing [N6 salts (Sigma), B5 vitamins (Sigma), 2mg/I 2,4-D and 3% sucrose]. The rice seeds were incubated for 10 days to induce callus formation. Primary callus was dissected from the seeds and placed on RCI for 3 weeks. This was 15 done twice more to generate secondary and tertiary callus which was used for bombardment and continued subculture. A callus of 1-4mm diameter was placed in a 4cm circle on RCI with 0.3M mannitol 0.3M sorbitol for 5-24 hrs prior to bombardment. Microprojectile bombardment was carried out using the Biolistic PDC-1 000/He system (Bio-Rad). The procedure requires 1.5 mg gold particles (60 ug/ml) coated with 2.5 ug 20 DNA. DNA-coated gold particles were bombarded into rice calli with a He pressure of 11 00psi. After bombardment, the callus was allowed to recover for 48 hrs and then transferred to RCI with 30 mg/l hygromycin B for selection and incubated in the dark for 45 days at 26 0 C. Transformed calli were selected and transferred to RCI (minus 2,4-D) containing 5 mg/l ABA, 2 mg/l BAP, I mg/l NAA and 30mg/I hygromycin B for 9-12 25 days. Transformed calli were transferred to regeneration medium consisting of RCI (minus 2,4-D), 3 mg/I BAP, and 0.5 mg/I NAA without hygromycin B and cultured under continuous lighting conditions fro 2-4 weeks. Regenerated plantlets (1-3 cm high) were transferred to rooting medium whose concentration was half that of MS medium (Sigma) plus 1% sucrose and 0.05 mg/l NAA. After 2 weeks on rooting medium, the plantlets 30 developed roots and the shoots grew to about 10 cm. The plants were transferred to a 6.5 x 6.5 cm pots containing a mix of 50% commercial soil (Sunshine #1) and 50% soil from rice fields. The plants were covered by a plastic container to maintain nearly 100% humidity and grown under continuous light for 1 week. The transparent plastic cover WO 2004/099405 PCT/US2003/009209 -24 was slowly shifted over a 1 day period to gradually reduce humidity and water and fertilizers added as necessary. When the transgenic RO plants were approximately 20 cm in height, they were transferred to a greenhouse where they grew to maturity. Individual RI seed grains from the individual RO regenerated plants were 5 dissected into embryos and endosperms. Expression levels of recombinant blood proteins (AAT and fibrinogen poypeptides) in the isolated rice endosperms were determined. Embryos from the individual RI grains with high recombinant protein expression were sterilized in 50% bleach for 25 min and washed with sterile distilled water. Sterilized embryos were placed in a tissue culture tube containing 2 MS basal 10 salts with the addition of 1% sucrose and 0.05 mg/I NAA. Embryos were germinated and plantlets having -7 cm shoots and healthy root systems were obtained in about 2 weeks. Mature R1 plants were obtained as regenerants. EXAMPLE2 15 Production of rice extract containing recombinant blood proteins and its use in parenteral and enteric formulations General procedure for production of rice extract Transgenic rice containing heterologous polypeptides can be converted to rice extracts by either a dry milling or wet milling process. In the dry milling process, 20 transgenic paddy rice seeds containing the heterologous polypeptides were dehusked with a dehusker. The rice was grounded into a fine flour though a dry milling process, for example, in one experiment, at speed 3 of a model 91 Kitchen Mill from K-TEC. Phosphate buffered saline ("PBS"), containing 0.135 N NaCl, 2.7 mM KCI, 10 mM Na 2
HPO
4 , 1.7 mM KH 2
PO
4 , at pH 7.4, with or without additional NaCl, such as 0.35 N 25 NaCI, was added to the rice flour. In some experiments, approximately 10 ml of extraction buffer was used for each 1 g of flour. In other experiments, the initial flour/buffer ratio varied over a range such as 1 g/40 ml to 1 g/1 0 ml. The mixture was incubated at room temperature with gentle shaking for 1 hr. In other experiments, the incubation temperature was lower or higher, such as from about 220C to about 600C, 30 and the incubation time was longer or shorter, such as from about 10 minutes to about 24 hr. A Thermolyne VariMix platform mixer set at high speed was used to keep the particulates suspended.
WO 2004/099405 PCT/US2003/009209 -25 In place of PBS, other buffers such as ammonium bicarbonate, were used in some experiments.. In one embodiment, 10 liters of 0.5M ammonium bicarbonate was added to 1 kg of rice flour. The resulting homogenate was clarified either by filtration or centrifugation. For 5 the filtration method, the mixture was allowed to settle for about 30 minutes at room temperature, after which the homogenate was collected and filtered. Filters in three different configurations were purchased from Pall Gemansciences and used. They were: a 3 ptm pleated capsule, a 1.2 pm serum capsule and a Suporcap capsule 50 (0.2 pm). For centrifugation, a Beckman J2-HC centrifuge was used and the mixture was 10 centrifuged at 30,000 g at 40C for about 1 hr. The supernatant was retained and the pellet discarded. In one embodiment, the filtrate and supernatant were further processed, for example by ultra-filtration or dialysis or both to remove components such as lipids, sugars and salt. 15 The filtrate from the above filtration procedure, which is also called the clarified extract, was then concentrated using a spiral wound tangential flow filter operated in a batch recirculation mode. In one embodiment, PES (polyethersulfone) 3000-4000 molecular weight cutoff membranes were used for this step. These final concentrated extracts were held overnight in a cold room. 20 The concentrated extracts were next dried to a powder by lyophilization. The lyophilized material was scraped from the lyophilizer trays and combined into a plastic bag. The dry material was compressed by drawing a vacuum on the bag and then the material was blended and the particle size reduced by hand-kneading it through the plastic. 25 Rice extract can also be produced using a wet milling procedure. Transgenic paddy rice seeds containing recombinant human blood protein can be re-hydrated for a period of 0 to 288 hrs at 300C. The rehydrated seeds are ground in PBS extraction buffer. The initial seed/buffer ratio can vary over a range such as 1 g/40 ml to 1 g/1 0 ml. 30 Over 20% human blood protein can be recovered from the wet milling process. The result of the wet milling becomes an initial extract that may be kept cold (4*C) or stored frozen until use depending on the stability of the blood protein target. The WO 2004/099405 PCT/US2003/009209 -26 processing of initial extract to obtain dried extract is the same as that described for dry milling in this section. EXAMPLE 3 5 Concentration and diafiltration of recombinant blood protein and control rice extracts. The conditions used in concentration and diafiltration vary depending on volume, speed,. cost, etc. These conditions are standard in the art based on the description herein. The frozen initial extract was thawed in the coldroom (about 2-80C) for six hours. The thawed material was clarified though a 0.45 ptm filter and concentrated 10 using a 5000 Nominal Molecular Weight Cutoff membrane of Polyethersultone. 90 ml of the filtrate of control extract was concentrated to 10 ml and additional 10 ml of deionized water can be added to the concentrated filtrate. The diluted filtrate can be diafiltrated one more time using water. The precipitate starts forming at 16 mS and. increases as the ionic strength decreases. A solution of 1.OM ammonium bicarbonate 15 was added to the retentate to add ionic strength. The haze decreases although does not disappear completely. The material was diafiltered multiple times, in one embodiment three times, with water and multiple times, in one embodiment three times, with 0.1 M ammonium bicarbonate. It was concentrated to 9 ml and the membrane is rinsed with 0.1 M ammonium bicarbonate. The concentrate was filtered through 20 several 0.2 ptm button filters. In one embodiment, 2.3 ml of the filtrate is lyophilized as is; 2.3 ml of the filtrate is diluted to 12 ml with deionized water and lyophilized, and 2.0 ml of the filtrate is diluted to 25 ml with deionized water and lyophilized. All the filtrates remained clear. A total of 89 ml of the filtrate of recombinant protein extract was concentrated to 25 10 ml, and additional 10 ml of 0.1 M ammonium bicarbonate is added. The resulting mixture is concentrated back to 10 ml and another 10 ml of 0.1 M ammonium bicarbonate is added. The retentate starts to haze up. The material was diafiltered multiple times, in one embodiment three times, with 0.1 M ammonium bicarbonate. It was concentrated to 9 ml and the membrane is rinsed with 0.1 M ammonium 30 bicarbonate. The concentrate was filtered through several 0.45 pm button filters. In one embodiment, 2.0 ml of the filtrate was lyophilized as is; 2.0 ml of the filtrate was diluted to 12 ml with deionized water where a haze formed, and lyophilized, and 2.0 ml WO 2004/099405 PCT/US2003/009209 -27 of the filtrate was diluted to 12 ml with 0.1 M ammonium bicarbonate that remained clear, and lyophilized. EXAMPLE 4 .5 Comparison of trial extraction of recombinant protein rice with PBS and ammonium bicarbonate The conditions used in concentration and diafiltration vary depending on volume, speed, cost, etc. These conditions are all standard in the art based on the description. herein. Recombinant protein rice flour is mixed with extraction buffer at about 100 g/L 10 for about 1 hour using a magnetic stir bar. In one 2L beaker, the extraction buffer is PBS, pH 7.4 plus 0.35 M NaCl. In another 2L beaker, the extraction buffer is 0.5 M ammonium bicarbonate. A 15 cm Buchner funnel is pre-coated with about 6g of Cel pure C300 before adding another 20g of Cel-pure C300. The mixture is filtered at about 3-4 Hg. It is then washed twice with about 100 ml of respective extraction buffer.- The 15 extracted filtrate is collected and concentrated with ultra-filtration cartridges: 5K Regenerate Cellulose, 5K PES, and I K Regenerated Cellulose. The concentrates are lyophilized and analyzed for recombinant blood protein activity contents. The ammonium bicarbonate and PBS, pH7.4 plus 0.35 M NaCI both extract approximately the same amount of rAAT. There is little loss of recombinant protein units in the 20 permeate with any of the ultrafiltration units that were used. Other extraction buffer can also be used to extract recombinant proteins expressed in transgenic rice grains, for example Tris buffer, ammonium acetate, depending on applications. 25 EXAMPLE 5 Production of rice extracts containing recombinant blood proteins The conditions used in concentration and diafiltration vary depending on volume, speed, cost, etc. These conditions are all standard in the art based on the description herein. All equipment is soaked in hot 0.1 M NaOH at a starting temperature of about 30 55 0 C. Rice flour is added to an about 250-500 gal stainless steel tank containing 0.5M ammonium bicarbonate in a ratio of 95-105 g/L. It is mixed for about 60-80 minutes at about 9 0
C.
WO 2004/099405 PCT/US2003/009209 -28 12 plates of 36 inch filter press C300 were pre-coated with about 3-6 kg Cel-pure C300. About 19-26 g/L of Cel-pure is added to the extract and mixed thoroughly. The mixture is pressed at a pressure of about 22 psi at a flow rate of about 82 liters/minute. The filtrate is collected into a 250 gal stainless steel tank and washed with 0.5M 5 ammonium bicarbonate. The press is blown dry. This process is carried out at about 10 C. The 300 NMW cut-off membranes (Polysulfone), which had been cleaned and stored with 0.1 M NaOH after control run is rinsed thoroughly with deionized water. The extract is concentrated and bumped to a 100 gal stainless steel tank. The membrane 10 and the concentration tank were flushed with 0.1 M ammonium bicarbonate to recover all remaining extract. The products were covered with plastic and left in the 100 gal tank overnight at room temperature. The concentrate is filtered through spiral wound 1 tm filter and into 5 gal poly container. 15 EXAMPLE6 Blending of rice extract containing recombinant proteins into parenteral, inhalant, intranasal and topical formulations. Recombinant blood proteins (such as AAT) can be highly purified grains from cereal grains for use in medical/pharmaceutical applications. A purification protocol for 20 rice seed extract expressed human AAT has been developed [Huang et al, 2002], consisting of preparing a rice seed extract according to the above examples and further purifying the extract preparation using Con-A, DEAE and Octyl Sepharose chromatography respectively. AAT can be purified to greater than 90% homogeneity utilizing such a procedure [Huang et al, 2002]. Purified AAT can be utilized in potential 25 pharma/medical applications for the following indications: AAT augmentation/replacement therapy [Sandhaus, 1993; Hubbard et al, 1989], cystic fibrosis [McElvaney et al,1991; Allen,1996], psoriasis, panniculitis and cutaneous vasculitis [O'Riordan et al, 1997; Dowd et a/, 1995] and pulmonary inflammation [Bingle and Tetley, 1996]. For some of these indications, purified AAT protein preparations can 30 be administered via intravenous (iv) methods in 0.09% saline solution. Alternatively, the saline solution solution could be buffered with serum albumen at 0.5% or some other pharmacologically acceptable protein carrier molecule. AAT dosages are usually around 60 mg/kg. For aerosol delivery, an aerosol generating system can be employed utilizing WO 2004/099405 PCT/US2003/009209 -29 a compressed air driven nebulizer selected on the basis of the basis of its ability to generate an aerosol with droplets of the optimum size (< 3um in aerodynamic diameter) for deposition in the lower respiratory tract [Hubbard et al, 1989]. Again proteins can either be suspended in sterile water or a buffered saline solution containing a 5 pharmacologically acceptable protein carrier. Alternatively, a dried protein powder containing the purified protein component could be utilized as the dispersal agent and this could be an a rice based extract where the AAT component is greater but not less then 50% by weight. In another case, recombinant rice expressed and extracted human blood proteins 10 such as AAT and fibrinogen can be employed topically. The use of fibrin sealants/bandages has been a widely accepted used by the medical community. Fibrin sealants are effective hemostatic agents [Mankad and Codispoti, 2001], a means for achieving tissue adhesion, preventing fluid accumulation and promotion of wound healing [Spotnitz, 20011. Fibrin sealants can also be used as a means of slowly 15 releasing medications, including antibiotics, growth factors and other agents [Spotnitz, 1997]. Rice expressed fibrinogen can also provide a potential low cost and animal virus free source for these indications. References 20 1. Allen, E.D. (1996). Opportunities for the use of aerosolized a1 -antitrypsin for the treatment of cystic fibrosis. CHEST 110: 256S-260S. 2. Ausubel F.M. et al., CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, New York, N.Y., 1993. 3. Beatty, K., Beath, J. and Travis, J. (1980). Kinetics of association of serine 25 proteinase with native and oxidized a-1-proteinase inhibitor and a-1 antichymotrypsin. Jour Biol Chem 255: 3931-34. 4. Bednarek, S.Y. and Raikel, N.V. (1992). Intracellular trafficking of secretory proteins. Plant Mol Biol 20: 133-50. 5. Bhagavan, N.V. (2002). "Biochemistry of Hemostatis" in Medical Biochemistry, 30 Academic Press Inc, Harcourt Inc, Orlando, Fla. 6. Bhagavan, N.V. (2002). "Molecular Immunology" in Medical Biochemistry, Academic Press Inc, Harcourt Inc, Orlando, Fla.
WO 2004/099405 PCT/US2003/009209 -30 7. Bingle, L. and Tetley, T.D. (1996). Secretory leukoprotease inhibitor; partnering al -proteinase inhibitor to combat pulmonary inflammation. Thorax 51:1273-4. 8. Brennan, S.O., Owen, M.C., Boswell, D.R., Lewis, J.H. and Carrell, R.W. (1984). Circulating proalbumin associated with a variant proteinase inhibitor. Biochem 5 Biophys Acta 802: 24-28. 9. Brown, J.H., Volkmann, N., Jun, G., Henschen-Edman, A.H. and Cohen, C. (2000). The crystal structure of modified bovine fibrinogen. Proc Natl Acad Sci 97: 85-90. 10. Carrell, R.W., Jeppsson, J.O., Vaughan, L., Brennen, S., Owen, M.C. and 10 Boswell, D.R. (1981). Human a-I -antitrypsin: Carbohydrate attachment and sequence homology. FEBS Lett 135: 301-3. 11. Carrell, R.W., Jeppson, J.O., Laurrell, C.B., Brennan, S.O., Owen, M.C., Vaughan, L. and Boswell, D.R. (1982). Structure and variation of human alpha-1 antitrypsin. Nature 298: 329-34. 15 12. Chrispeels, M.J. (1991). Sorting proteins in the secretory system. Annu Rev Plant Physiol Plant Mol Biol 42: 21-53. 13. Chrispeels, M.J. and Raikhel, N.V. (1992). Short peptide domains target proteins to plant vacuoles. Cell 68: 613-16. 14. Christou, P. (1992). Genetic transformation of crop plants using microprojectile 20 bombardment. Plant Jour 2: 275-281. 15. Daniell, H., Streatfield, S.J. and Wycoff, K. (2001). Medical molecular farming: production of antibodies, biopharmaceuticals and edible vaccines in plants. TRENDS Plant Sci 6: 219-226. 16. Davidson L.A. and Lonnerdal, B. (1987). Persistence of human milk proteins in 25 the breast-fed infant. Act Pediatric Scand 76: 733-40. 17. Ditta, G., Stansfield, S., Corbin, D. and Helinski, D.R. (1980). Broad host ramge DNA cloning system from gram-negative bacteria: Construcyionof a gene bank from Rhizobium melloti. Proc Natl Acad ,Sci USA 77: 7347-51. 18. Dowd, S.K., Rodgers, G.C. and Callen, J.P. (1995). Effective treqatment with a1 30 protease inhibitor of chronic cutaneous vasculitis associated with al -antitrypsin deficiency. Jour Am Acad Dermatol 33: 913-6. 19. Eriksson, S. (1964). Acta Medic Scand 175: 197-205.
WO 2004/099405 PCT/US2003/009209 -31 20. Everse, S.J., Spraggon, G.,.Veerapandian, L. and Doolittle, R.F. (1999) Conformational changes in fragments D and doubl-D from human fibrinogen upon binding the peptide ligan Gly-His-Pro-amide. Biochemistry 38: 2941-2946. 21. Friezner-Degen S.J., MacGillivray, R.T.A. and Davie, E.W. (1983). 5 Characterization of the complementary deoxyribonucleic acid and gene coding for human prothrombin. Biochemistry 22: 2087-97. 22. Holmberg, N., Gosta, L, Bailey, J.E. and Bulow, L. (1997). Transgenic tobacco expressing Vitreoscilla hemoglobin exhibits enhanced growth and altered metabolite production. Nature Biotech 15: 244-7. 10 23. Hiatt, A., Cafferkey, R. and Bowdish, K. (1989). Production of antibodies in transgenic plants. Nature 342: 76-8. 24. Hiatt, A. and Ma, J.K.C. (1992). Monoclonal antibody engineering in plants. FEBS Letters 307: 71-5. 25. Horvath, H., Huang, J., Wong. 0., Kohl E., Okita, T., Kannangara, C.G. and 15 vonWettstein, D. (2000). The production of recombinant proteins in transgenic barley grains. Proc Natl Acad Sci USA 97: 1914-19. 26. Huang, N., Simmons, C.R. and Rodriguez, R.L. (1990). Codon usage patterns in plant genes. J CAASS 1: 73-86. 27. Huang, N., Wu, I., Nandi, S., Bowman, E., Huang, J., Sutliff, T. and Rodriguez, 20 R.L. (2001). The tissue-specific activity of a rice B-glucanase promoter (Gns9) is used to select rice transformants. Plant Sci 161: 589-95. 28. Huang, J., Sutliff, T.D., Wu, L., Nandi, S., Benge, K., Terashima, M., Ralston, A.H., Drohan, W., Huang, N. and Rodriguez, R.L. (2001). Expression and purification of functional human a-1-antitrypsin from cultured plant cells. Biotechnol 25 Prog 17: 126-33. 29. Hubbard, R.C., McElvaney, N.G., Sellers, S.E., Healy, J.T., Czerski, D.B. and Crystal, R.G. (1989). Recombinant DNA-produced al-antitrypsin administered by aerosol augments lower respiratory tract antineutrophil elastase defenses in individuals with al-antitrypsin deficiency. Jour Clinical Invest 84: 1349-54. 30 30. Jouanin, L., Vilaine, F., d'Enfert, C. and Casse-Delbart, F. (1985). Localization and restriction maps of the replication origin regions of the plasmids ofAgrobacterium rhizogenes strain A 4 . Mol Gen Genet 201: 370-4.
WO 2004/099405 PCT/US2003/009209 -32 31. Judah, J.D., Gamble, M. and Steadman, J.H. (1973). Biosynthesis of serum albumin in rat liver, evidence for the exsistance of 'proalbumin'. Biochem J 134: 1083-91. 32. Kurachi, K., Chandra, T., Oegen, S.J., White, T.T., Marchioro, T.L., Woo, S.L. 5 and Davie, E.W. (1981). Cloning and sequence of a cDNA coding for x-1-antitrypsin. Proc Natl Acad Sci 78: 6826-30. 33. Ma, J.K.C., Hiatt, A., Hein, M., Vine, N.D., Wang, F., Stabila, P., van Dolleweerd, C., Mostov, K. and Lehner, T. (1995). Generation and assembly of Secretory Antibodies in plants. Science 268: 716-9. 10 34.- Madrazo, J., Bzrown, J.H., Litvinovich, S., Dominguez, R., Yakovlev, S., Medved, L. and Cohen, C. (2001) Crystal structure of the central region of bovine fibrinogen E5 fragment at 1.4 A resolution. Proc Nati Acad Sci 98: 11967-72. 35. Mankad, P.S. and Codispoti, M. (2001). The role of fibrin sealants in hemostasis. Amer Jour Surg 182: 21S-28S. 15 36. McBride, K.E. and Summerfelt, K.R. (1990). Improved binary vectors for Agrobacterium mediated plant transformation. Plant Mol Biol 14: 269-76. 37. McElvaney, N.G., Hubbard, R.C., Birrer, P., Chernick, M.S., Caplan, D.B., Frank, M.M. and Crystal, R.G. (1991). Aerosol al-antitrypsin treatment for cystic fibrosis. The Lancet 337: 392-4. 20 38. McGilligan, K.M., Thomas, D.W. and Eckert, C.D. (1987). Alpha-1-antitrypsin concentration in human milk. Pediatr Res 22: 268-70. 39. O'Riordan, K., Blei, A., Rao, M.S. and Abecassis, M. (1997). al-antitrypsin deficiency-associated panniculitis. Transplant 63: 480-2. 40. Peters, T.J. (1996). All About Albumin: Biochemistry, genetics and medical 25 applications. Academic Press Inc, Harcourt Brace & Company, Orlando, Fla. 41. Rabiet, M.J., Blashill, A., Furie, B. and Furie, B.C. (1986). Prothrombin fragment 1*2*3; a major product of prothrombin activation in human plasma. Jour Biol Chem 261: 13210-15. 42. Rosenberg, J.S., Beeler, D.L. and Rosenberg, R.D. (1975). Activation of human 30 prothrombin by highly purified human factors V and X, in the presence of human antithrombin. Jour Biol Chem 250: 1607-17.
WO 2004/099405 PCT/US2003/009209 -33 43. Travis, J. and Salvesen, G.S. (1983). Human plasma proteinase inhibitors. Annu Rev Biochem 655-709. 44. Sambrook J. et al., MOLECULAR CLONING: A LABORATORY MANUAL (Second Edition), Cold Spring arbor Press, Plainview, N.Y, 1989. 5 45. Sandhaus, R.A. (1993). "Alpha-1 -antitrypsin augmentation therapy" in Proteases, Protease Inhibitors and Protease-Derived Peptides, Birkhauser Verlag, Basel, pp 97-102 Sanford, J., Smith, F.D. and Russell, J.A. (1993). Optimizing the biolistic process for different biological applications. Meth Enzymol 217: 83-509. 46. Shieh, M.W., Wessler, S.R. and Raikel, N.V. (1993). Nuclear targeting of the 10 maize R protein requires two nuclear localization sequences. Plant Physiol 101: 353-61. 47. Sijmons, P.C., Dekker, B.M., Schrammeijer, B., Verwoerd, T.C., van den Elzen, P.J.M. and Hoekema, A. (1990). Production of correctly processed human serum albumin in transgenic plants. Bio/Technology 8: 217-21. 15 48. Smeekens, S., Bauerle, C., Hageman, J., Keegstra, K. and Weisbeek, P. (1986) The role of the transit peptide in the routing of precursors towards different chloroplast compartments. Cell 46: 365-76. 49. Spotnitz, W.D. (1997). New developments in the use of fibrin sealants: a surgeon's perspective. Jour Long Term Effects Med Implants 7: 243-53. 20 50. Spotnitz, W.D. (2001). Commercial fibrin sealants in surgical care. Amer Jour Surg 182: 8S-14S.Vine, N.D., Drake, P., Hiatt, A. and Ma, J.K.C. (2001). Assembly and plasma membrane targeting of recombinant immunoglobin chains in plants with a murine immunoglobin transmembrane sequence. Plant Molec Biol 45: 159-67. 51. Tietz, N.W. (1995). Clinical Guide to Laboratory Tests, W.B. Saunders, 25 Philadelphia. 52. Varagona, M.J., Schmidt, R.J. and Raikhel, N.V. (1992). Nuclear localization signals required for nuclear targeting of the maize regulatory protein, Opaque-2. Plant Cell 4: 1213-27. 53. Vitale, A. and Chrispeels, M.J. (1992). Sorting of proteins to the vacuoles of 30 plant cells. BioEssays 14: 151-60. 54. Wassmen, C.C., Reiss, B., Bartlett, S.G. and Bohnert, H.J. (1986). The importance of the transit peptides and the transported protein for protein import into chloroplasts. Mol Gen Genet 205: 446-53.
WO 2004/099405 PCT/US2003/009209 -34 55. Weeke, B. and Krasilnikoff (1971). A polynomial expression for the serum concentrations of 21 serum proteins from 1 to 93 years of age in normal males and females. Protein Biol Fluids 18: 173-9. 56. Yakovlev, S., Litvinovich, S., Loukinov, D. and Medved, L. (2000). Role of the 5 beta-strand in the central domain of fibrinogen gamma module. Biochemistry 39: 15721-9. 57. Yang, Z., Mochalkin, i., Veerapandian, L., Riley, M. and Doolittle, R.F. (2000) Crystal structure of native chicken fibrinogen at 5.5 A resolution. Proc Natl Acad Sci 97: 3907-12. 10 All publications cited herein are expressly incorporated herein by reference.
Claims (18)
1. A method of producing a recombinant human blood protein in monocot plant seeds, comprising the steps of: (a) transforming a monocot plant cell with a chimeric gene comprising (i) a promoter from the gene of a maturation-specific monocot plant storage protein, (ii) a first DNA sequence, operably linked to said promoter, encoding a monocot plant seed-specific signal sequence capable of targeting a polypeptide linked thereto to a monocot plant seed endosperm cell, and (iii) a second DNA sequence, linked in translation frame with the first DNA sequence, encoding a human blood protein, wherein the first DNA sequence and the second DNA sequence together encode a fusion protein comprising an N-terminal signal sequence and the human blood protein; (b) growing a monocot plant from the transformed monocot plant cell for a time sufficient to produce seeds containing the human blood protein; and (c) harvesting the seeds from the plant, wherein the human blood protein constitutes at least about 3.0% of the total soluble protein in the harvested seeds.
2. The method of claim 1, wherein the human blood protein constitutes at least about 5.0% of the total soluble protein in the harvested seeds.
3. The method of claim 1, wherein the human blood protein constitutes at least about 10.0% of the total soluble protein in the harvested seeds.
4. The method of claim 1, further comprising purifying the human blood protein from the harvested seeds.
5. The method of claim 1, wherein the human blood protein is selected from the group consisting of hemoglobin, alpha-1-antitrypsin, fibrinogen, human serum albumin, thrombin, an antibody, and a blood coagulation factor. WO 2004/099405 PCT/US2003/009209 -36
6. The method of claim 1, wherein the human blood protein produced in the method comprises one or more plant glycosyl groups.
7. A purified human blood protein obtained by the method of claim 1, wherein the human blood protein comprises one or more plant glycosyl groups.
8. The human blood protein of claim 7, selected from the group consisting of hemoglobin, alpha-1-antitrypsin, fibrinogen, human serum albumin, thrombin, an antibody, and a blood coagulation factor.
9. A monocot plant seed product selected from the group consisting of whole seed, flour, extract and malt, prepared from the harvested seeds obtained by the method of claim 1, wherein the human blood protein constitutes at least about 3.0% of the total soluble protein in the seed product.
10. The seed product of claim 9, wherein the human blood protein constitutes at least about 5.0% of the total soluble protein in the seed product.
11. The seed product of claim 9, wherein the human blood protein constitutes at least about 10.0% of the total soluble protein in the seed product.
12. The seed product of claim 9, wherein the human blood protein is selected from the group consisting of hemoglobin, alpha-1-antitrypsin, fibrinogen, human serum albumin, thrombin, an antibody, and a blood coagulation factor.
13. A composition comprising a purified human blood protein comprising at least one plant glycosyl group and at least one pharmaceutically acceptable excipient or nutrient, wherein the human blood protein is produced in a monocot plant containing a nucleic acid sequence encoding the human blood protein and is purified from seed harvested from the monocot plant, and wherein the at least one nutrient is from a source other than the monocot plant. WO 2004/099405 PCT/US2003/009209 -37
14. The composition of claim 13, wherein the human blood protein is selected from the group consisting of hemoglobin, alpha-1-antitrypsin, fibrinogen, human serum albumin, thrombin, an antibody, and a blood coagulation factor.
15. The composition of claim 13, wherein the composition is substantially free of contaminants of the monocot plant.
16. The composition of claim 13, wherein the at least one nutrient is selected from the group consisting of salts, saccharides, vitamins, minerals, amino acids, peptides, and proteins other than the human blood protein.
17. The composition of claim 13, wherein the composition is formulated for parenteral, enteric, inhalation, intranasal or topical delivery.
18. The composition of claim 13, wherein the composition is formulated for enteric delivery, contains at least one pharmaceutically acceptable excipient, and is non-nutritional.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2003/009209 WO2004099405A1 (en) | 2003-04-11 | 2003-04-11 | Human blood proteins expressed in monocot seeds |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2003218396A1 true AU2003218396A1 (en) | 2004-11-26 |
AU2003218396B2 AU2003218396B2 (en) | 2008-09-04 |
Family
ID=33434296
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2003218396A Ceased AU2003218396B2 (en) | 2003-04-11 | 2003-04-11 | Human blood proteins expressed in monocot seeds |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1651760A4 (en) |
JP (1) | JP2006522585A (en) |
AU (1) | AU2003218396B2 (en) |
CA (1) | CA2525493C (en) |
WO (1) | WO2004099405A1 (en) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2551392A1 (en) * | 2003-12-23 | 2005-07-28 | Ventria Bioscience | Methods of expressing heterologous protein in plant seeds using monocot non seed-storage protein promoters |
WO2006108830A2 (en) * | 2005-04-13 | 2006-10-19 | Bayer Cropscience Sa | TRANSPLASTOMIC PLANTS EXPRESSING α 1-ANTITRYPSIN |
CA3014139A1 (en) * | 2006-05-12 | 2007-11-22 | Monsanto Technology Llc | T-dna constructs for obtaining marker-free transgenic plants, and plants comprising such constructs |
US20110177524A1 (en) * | 2008-07-09 | 2011-07-21 | Profibrix Bv | Recombinant Fibrinogen |
CN102127164B (en) | 2010-12-20 | 2013-01-30 | 武汉禾元生物科技有限公司 | Method for extracting recombinant human serum albumin from rice seeds |
CN102532254B (en) | 2010-12-24 | 2015-06-24 | 武汉禾元生物科技股份有限公司 | Method for separating and purifying recombinant human serum albumin (rHSA) from rice seeds |
CN102994514B (en) * | 2012-11-07 | 2015-06-10 | 武汉禾元生物科技股份有限公司 | Method for producing, separating and purifying recombinant human antitrypsin (OsrAAT) from rice seeds |
CN103880947B (en) | 2012-12-21 | 2016-01-13 | 武汉禾元生物科技股份有限公司 | A kind of chromatography method of separating and purifying high-purity recombination human serum albumin |
SI3044320T1 (en) * | 2013-09-11 | 2020-07-31 | Impossible Foods Inc. | Secretion of heme-containing polypeptides |
NZ737094A (en) | 2015-05-11 | 2019-06-28 | Impossible Foods Inc | Expression constructs and methods of genetically engineering methylotrophic yeast |
CN109355291B (en) * | 2018-11-22 | 2022-01-18 | 深圳市作物分子设计育种研究院 | Identification and application of plant endosperm specific expression promoter pOsEnS93 |
CN114341351A (en) | 2019-04-25 | 2022-04-12 | 非凡食品有限公司 | Strains and methods for producing hemoprotein |
WO2024003668A1 (en) * | 2022-06-29 | 2024-01-04 | Moolec Science Limited | High expression of animal heme protein in plants |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5693506A (en) * | 1993-11-16 | 1997-12-02 | The Regents Of The University Of California | Process for protein production in plants |
FR2736930B1 (en) * | 1995-07-17 | 1997-09-19 | Biocem | PROCESS FOR THE PRODUCTION, BY PLANT CELLS, OF HEMINIC PROTEINS, PROTEINS THUS OBTAINED AND PRODUCTS CONTAINING THE SAME |
WO2002064750A2 (en) * | 2001-02-14 | 2002-08-22 | Ventria Bioscience | Expression system for seed proteins |
-
2003
- 2003-04-11 EP EP03714394A patent/EP1651760A4/en not_active Withdrawn
- 2003-04-11 JP JP2004571610A patent/JP2006522585A/en active Pending
- 2003-04-11 AU AU2003218396A patent/AU2003218396B2/en not_active Ceased
- 2003-04-11 CA CA2525493A patent/CA2525493C/en not_active Expired - Lifetime
- 2003-04-11 WO PCT/US2003/009209 patent/WO2004099405A1/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
JP2006522585A (en) | 2006-10-05 |
EP1651760A1 (en) | 2006-05-03 |
AU2003218396B2 (en) | 2008-09-04 |
CA2525493C (en) | 2018-10-30 |
CA2525493A1 (en) | 2004-11-18 |
EP1651760A4 (en) | 2006-10-18 |
WO2004099405A1 (en) | 2004-11-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8686225B2 (en) | Monocot seed product comprising a human blood protein | |
US7718851B2 (en) | Expression of human milk proteins in transgenic plants | |
US6991824B2 (en) | Expression of human milk proteins in transgenic plants | |
AU2003218396B2 (en) | Human blood proteins expressed in monocot seeds | |
US20100119691A1 (en) | Expression of human milk proteins in transgenic plants | |
US20160076048A1 (en) | Non-glycosylated transferrin expressed in monocots | |
AU2002250127B2 (en) | Expression of human milk proteins in transgenic plants | |
US6127145A (en) | Production of α1 -antitrypsin in plants | |
AU746826B2 (en) | Production of mature proteins in plants | |
WO2002064750A2 (en) | Expression system for seed proteins | |
Miao et al. | Plant bioreactors for pharmaceuticals | |
US20080010697A1 (en) | Methods of Expressing Heterologous Protein in Plant Seeds Using Monocot Non Seed-Storage Protein Promoters | |
AU2007216827B2 (en) | Expression of human milk proteins in transgenic plants | |
AU2012202697B2 (en) | Expression of human milk proteins in transgenic plants | |
Sutliff et al. | Production of α 1-antitrypsin in plants |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FGA | Letters patent sealed or granted (standard patent) | ||
MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |